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Human pancreatic neuroendocrine tumors are rare tumors that form in the endocrine 
pancreas. Patients with these tumors have limited therapeutic options, and curative 
intervention is limited to surgical resection. These tumors do, however, consistently express 
somatostatin receptor type 2 (SSTR2) making them vulnerable to somatostatin analogs. 
Exploiting cell surface receptors overexpressed in tumors is a common avenue for ligand-
directed delivery of imaging or therapeutic agents to tumors. In this regard, identification of 
novel ligand/receptor pairs with combinatorial peptide libraries has produced multiple 
candidates for clinical translation. Alternatively, here, we introduce a hybrid vector of 
adeno-associated virus and phage (AAVP) displaying a known, rationally chosen, 
biologically active peptide for the delivery of tumor necrosis factor (TNF). Our ligand, 
octreotide, is a somatostatin analog with specific affinity for SSTR2 that is currently used 
clinically for both imaging studies and the relief of symptoms associated with pancreatic 
neuroendocrine tumors. When displayed in AAVP, octreotide mediates selective 
internalization of the viral particles after systemic administration. We validated the 
internalization and transduction capabilities of the octreotide-targeted AAVP in a 
neuroendocrine tumor cell line expressing SSTR2. Additionally, we confirmed AAVP 
homing and TNF expression in vivo in a transgenic mouse model of pancreatic 
neuroendocrine tumor development that mimics human disease. With further investigation, 
therapeutic gene delivery using the octreotide/SSTR2 ligand/receptor pair could represent a 
viable clinical alternative for patients lacking adequate treatment options.  
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 The nature of bacteriophage (phage) makes it amenable to the discovery and 
characterization of ligand/receptor pairs, which has been described thoroughly over the past 
three decades. The originally described purpose of combinatorial phage libraries as tools for 
characterizing antibody epitopes [1-10] has expanded to include describing ligand/receptor 
pairs in individual proteins [11-20], cell lines [21-29], normal vasculature [30-35], as well as 
tumors in vivo [32, 36, 37]. Natural progression of the field of phage mapping and targeting 
raises the question: can the genetically modifiable nature of phage be exploited for targeted 
drug delivery using a known ligand/receptor pair? Furthermore, which ligand/receptor pair 
can be used for realization of this hypothesis? As described further in the following sections, 
there are many reasons for choosing the octreotide/somatostatin receptor type 2 (SSTR2) 
ligand/receptor pair as the first candidate for study. Briefly, these reasons include the known 
and repeatedly observed overexpression of SSTR2 in neuroendocrine tumors (NETs) 
broadly and pancreatic NETs specifically, the specificity of octreotide for SSTR2, an unmet 
clinical need for patient treatment options beyond the currently available, and the potential 
of octreotide-targeted imaging studies that are already standard diagnostic practice as a 
potential clinical bio-marker of treatment susceptibility.  
 Brazeau’s discovery of somatostatin in 1973 [38] and the ensuing investigation 
identified the therapeutic properties of somatostatin analogs in tumors overexpressing 
somatostatin receptors (SSTRs). This opened a new avenue for clinical intervention in 
pancreatic NETs previously limited to surgical resection. Somatostatin is a peptide hormone 
secreted from the endocrine pancreas to regulate glucose metabolism. Somatostatin is also 
secreted along the central nervous system and digestive tract, to regulate the production and 
secretion of pituitary and gastrointestinal hormones, respectively [39]. Tumors arising from 
these neuroendocrine cells often express one SSTR receptor family member, commonly 
SSTR2 [40], providing an avenue for ligand-directed imaging and therapeutic opportunities 
[41-49]. The half-life of circulating somatostatin is less than 3 minutes [50], eliminating its 
utility as a targeting agent and necessitating the development of synthetic analogs for 
clinical applications [51]. One such synthetic somatostatin analog, octreotide (amino acid 
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sequence FCFWKTCT), has a specific affinity for SSTR2 [52] and an increased half-life in 
circulation [52, 53], ensuring its clinical utility.  
Our strategy to selectively target SSTR2 employs an AAVP hybrid vector that 
combines genetic elements from adeno-associated virus (AAV) and bacteriophage (phage). 
Incorporating the octreotide peptide sequence into the phage region for display on the pIII 
viral coat protein enables internalization of the AAVP particles in tumor cells expressing 
SSTR2, specifically. An octreotide-targeted AAVP designed to incorporate tumor necrosis 
factor (TNF) into the cellular DNA, termed Oct-AAVP-TNF, acts as a therapeutic reporter 
gene, and, after systemic internalization, mediates expression of an apoptotic agent within 
the vulnerable vasculature of the pancreatic NETs without toxicity to normal organs.  
The category of human pancreatic NETs includes tumor manifesting in the course of 
multiple endocrine neoplasia type 1 (MEN1) syndrome. To evaluate the activity of our 
octreotide-targeted AAVP, we will use a Men1 transgenic mouse model that mimics tumor 
formation and disease progression observed in human MEN1 syndrome. Elimination of the 
Men1 tumor suppressor gene in the entirety of the pancreas results in tumor development in 
the endocrine pancreas but no pathological abnormalities evident in the exocrine tissue, 
similar to what is found in human patients [54], providing a preclinical model for studying 
our AAVP in vivo in the context of the complicated tumor microenvironment of pancreatic 
NETs. 
The expression of cell-surface receptors provides an avenue for targeted drug 
delivery specifically to the tumor eliminating toxicity to normal tissues, a goal in cancer 
treatment. Biotherapy with somatostatin analogs, particularly octreotide, is already used 
clinically for relief of symptoms associated with hormone hypersecretion in functioning 
tumors. Additionally, radiolabeled octreotide is also used to diagnose, localize, and stage 
pancreatic NETs. Exploiting the known, biologically active, and rationally chosen 
octreotide/SSTR2 ligand/receptor pair for the delivery of the TNF gene represents a viable 
alternative for patients lacking treatment options. This led us to hypothesize that displaying 
the octreotide peptide in the AAVP gene delivery system would recapitulate the specific 
binding attributes of the parental peptide, enabling ligand-directed delivery of a therapeutic 
agent to pancreatic NETs expressing SSTR2. The following sections will establish the 
rationale for the selection of the octreotide/SSTR2 ligand/receptor pair in greater detail and 
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clarify the current clinical utility of such an agent, provide an analysis of the suitability of 
AAVP as our gene delivery agent, and describe the Men1 transgenic mouse model and 
refine its applicability as our preclinical mouse model. Following these sections, the 
experimental protocols used to prepare and evaluate the octreotide-targeted AAVP-TNF will 
be described. The validation of Oct-AAVP-TNF activity in vitro and in vivo will be 
presented in the results section, confirming construction of the hybrid vector as well as 
specific homing and gene delivery. Finally, the conclusions drawn from our results, the 
further experimental plans for the octreotide-targeted AAVP, and the potential broader 
applications of both the Oct-AAVP-TNF and the untapped opportunities for the 
incorporation of biologically active peptides into the phage system will be presented as an 











 The pancreas is located in the epigastric region of the abdomen. Necessarily for its 
digestive functions, it the head of the pancreas sits in the curve of the duodenum and extends 
to rest behind the stomach. The pancreas can be divided into two functional components: 
exocrine and endocrine. The exocrine pancreas comprises the vast majority, more than 95 
percent, of total pancreas volume and is defined by the acini glands that secrete digestive 
enzymes to the small intestine to facilitate digestion. The endocrine pancreas is defined by 
the production and secretion of hormones into the bloodstream for actions throughout the 
body. Small cell populations, termed the islets of Langerhans, distributed throughout the 
pancreas, designate the endocrine pancreas [55].  
 The composition of cells in the human islets is heterogeneous and incredibly variable 
from islet to islet within a single pancreas and between multiple pancreases [56-67]. The 
combined effects of the islet cells and the hormones they produce are responsible for 
regulating glucose metabolism [68]. The large population of beta cells is responsible for 
insulin production. The alpha cells produce glucagon [69, 70], and the small population of 
delta cells is responsible for somatostatin production [71-75]. Additional cell types are also 
present in small numbers in the human islets. These cells include the pancreatic polypeptide 
(PP) -producing cells [76, 77] and the ghrelin [78] -producing epsilon cells [79-82] and 
make up less than five percent of the total islet cellular population [56, 61]. 
 Analysis of organogenesis reveals both the exocrine and endocrine pancreas is derived 
from a common progenitor cell [83-85]. Transcription factors in the gut during 
embryogenesis activate the necessary signaling pathways for cellular differentiation. In 
addition to analysis of human fetal pancreas development [86-91], time course and 
transcription factor expression during pancreatic development has been studied in numerous 
model organisms. These mechanisms are tightly regulated to ensure the correct formation of 
the pancreas [83, 85, 90, 92-109]. Specifically, in pancreatic differentiation, the pancreatic 
and duodenum homeobox 1 (PDX1; previously GSF, IPF1, IUF1, IDX-1, MODY4, PDX-1, 
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and STF-1) transcription factor is expressed in mice at embryonic day 8.5 (E8.5) [110-112], 
which coincides with total pancreas derivation from gut epithelium at E9.5 [100, 113-116]. 
This early time-point, along with further analyses, denote PDX1 expression essential for all 
epithelial cells of the pancreas, both exocrine and endocrine in function [111-113, 117-124]. 
The importance of PDX1 expression is further revealed in knockout mice wherein mice 
lacking PDX1 were born without a pancreas [114, 125, 126]. Loss of PDX1 has also been 
indicated as detrimental to pancreas development in humans [127]. Critical roles have also 
been identified multiple additional proteins, including those of the neurogenin 3 
(NEUROG3; previously ngn3, NGN-3, Atoh5, Math4B, and bHLHa7) [95, 113, 128-141], 
notch family members [128, 129, 142-156], sonic hedgehog (SHH; previously TPT, HHG1, 
HLP3, HPE3, SMMCI, TPTPS, and MCOPCB5) [157-164], and pancreas specific 
transcription factor 1a (PTF1A; previously bHLHa29 and PTF1-p48) [118, 165-174] 
signaling pathways, that act in a delicate balance during organogenesis for cellular 
differentiation and lineage determination [175-177]. Upon pancreatic differentiation from 
progenitor cells in the gut, cells disperse through the developing pancreatic tissue and 
proliferate to form the islets as clusters located throughout the pancreas [85, 89, 91, 105, 
115, 178, 179]. Simultaneous to organogenesis and cellular differentiation, blood vessel 
formation in the budding pancreas also encourages growth and development [174, 180-187].
 The pancreas, necessitated by its role as an endocrine organ, is highly vascularized, 
allowing for the dissemination of hormones and other neural transmitters via the 
bloodstream [63, 65, 184, 188-193]. Pancreatic vascularization is tightly regulated [194] and 
becomes evident in mice around E14 [85, 105, 186] and islet vascularization begins 
appearing at E15 [105]. Pancreatic capillaries in general are highly permeable [195, 196], 
with noticeable increases in both vascularization [180, 181, 190, 197-199] and permeability 
in islet blood vessels [200]. Capillaries of the islets also have a marked increase in both 
diameter [180, 190, 199, 201-204] and the number of fenestrations present along the 
endothelium [181, 204, 205]. Islet vasculature formation is also structured to allow for 
variability in blood flow in response to glucose [206-209] and other hormonal stimulation 
[209-214]. Multiple angiogenic factors present in islet tissue, including vascular endothelial 
growth factor (VEGF) family members and their receptors, could facilitate this discrepancy 
[180, 181, 183, 194, 215-220]. In addition to morphological differences, blood flow to the 
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islets constitutes five to fifteen percent of total pancreatic blood volume [197, 207, 221, 
222], which is remarkable because islet cell population is only around two percent of total 
pancreas volume [197, 221, 223-225].  
 
 
TUMORS ORIGINATING IN THE PANCREAS 
 
 The duality of the pancreas is further manifested in pancreatic tumors. Both the 
exocrine and endocrine pancreas can give rise to tumors, but the resulting tumors are 
markedly different. The vast majority, in excess of eighty percent, of tumors arising from the 
exocrine pancreas are pancreatic ductal adenocarcinomas [226-236], currently representing 
the fourth leading cause of cancer-related mortality in the United States [237, 238]. The 
overall five-year survival rate of patients diagnosed with pancreatic adenocarcinoma is less 
than five percent [226, 236-246]. These tumors are difficult to treat with more than eighty 
percent of pancreatic adenocarcinomas not resectable at diagnosis [234, 237, 242, 243, 247-
251]. Survival for patients with surgically resectable tumors only increases to around fifteen 
percent after five years [239, 241, 245, 248-268]. The unfavorable prognosis for patients 
diagnosed with pancreatic ductal adenocarcinoma is exacerbated by the frequency of this 
tumor type. 
 Alternatively, tumors arising from the endocrine pancreas make up less than five 
percent of all pancreatic tumor diagnoses [226, 230, 236, 269-271]. Tumors of the endocrine 
pancreas have a generally better prognosis than those of the exocrine pancreas, with a five-
year survival rate of from about 40 to 60 percent [226, 236, 270, 272-280]. However, this 
proportion remains moderately less than the overall survival at five years for all cancer sites 
combined of greater than 65 percent [281]. Median survival is also extended from four 
months for patients with exocrine tumors of the pancreas to more than two years for patients 
with endocrine tumors [232]. Not coincidentally, as opposed to pancreatic adenocarcinomas, 
which are considered stroma-rich and atypically avascular tumors [282-287], tumors of the 
endocrine pancreas are consistently vascularized [215, 288-293].  
 Endocrine tumors of the pancreas initiate an angiogenic cascade to enable the 
generation of new blood vessels corresponding to disease formation and progression in islet 
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cell tumors [215, 217, 290, 292, 294-305]. The new vascular network is random and 
disordered [291, 292, 297, 304, 306, 307], in agreement with observations of other 
malignancies [306, 308-313]. Tumor vascularization and angiogenesis are necessary for 
tumor development and sustainment [302, 308, 314-317], but tumors are consistently 
evolving to circumvent decreases to their blood supply and the corresponding limitations in 
oxygenation of the tumor cells and microenvironment while diminishing the efficacy of 
some therapeutic options [318-325]. The discrepancy in vascularization between tumors of 
exocrine and endocrine origin is significant but insufficient to describe the variability found 
in pancreatic malignancies. 
 
 
NEUROENDOCRINE TUMORS OF THE PANCREAS 
 
 Tumors originating in the endocrine pancreas have a variety of designations, including 
“neuroendocrine tumors (NETs) of the pancreas” for the much broader association and 
classification of tumors arising from the many endocrine organs; “gastroenteropancreatic 
(GEP) tumors” for the class of tumors originating from the gastrointestinal (GI) system, 
stomach, and pancreas; the historical “carcinoid tumor”; and the more descriptive pancreatic 
designations “pancreatic endocrine tumors” and “islet cell tumors” [326-328]. These are rare 
neoplasms with incidences reported historically ranging from two to twelve individuals of 
every million [236, 269-271, 277, 327, 329-339]. The number of tumors identified at 
autopsy is occasionally higher, however, indicating the possibility of a greater incidence of 
asymptomatic pancreatic NETs [339-341]. 
 Histological classification of pancreatic NETs includes three categories. Well-
differentiated NETs have either benign or low-grade malignancy potential, while poorly 
differentiated tumors are considered a high-grade malignancy [342-344]. Additionally, there 
are two broad categories generally used to describe pancreatic NETs: functioning and non-
functioning tumors [328, 345, 346]. Table 1 summarizes the various tumor types and their 
clinical characteristics. Functioning tumors produce excess hormones corresponding to the 
islet cell type the tumor originates from [336, 345, 347, 348]. Additionally, endocrine 











‡ Clinical symptom(s)§ 




















Glucagonoma 1 - 7 > 70 Glucagonoma syndrome 
Rash, diabetes, 
cachexia 




























PPoma < 1 - 2 > 80 None Abdominal pain, diarrhea 
* [269, 273, 274, 327, 338, 339, 348-362] 
†  [334, 351, 355, 363-370]  
‡  [352, 371-380]  
§  [289, 334, 355, 367, 381-385] 
 
Table 1. Tumor types and clinical characteristics of pancreatic NETs [269, 326, 334, 337, 
339, 352, 367, 386, 387]  	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(GI) tract, including gastrin, serotonin, and vasoactive intestinal peptide (VIP) leading to 
speculation of a common precursor or stem cell population [361, 370, 388-392]. The 
hormones secreted from tumors forming from these various cell types is then used to 
designate the type of functioning tumor [329, 337, 393, 394]. The significance of functional 
status is evident in the clinical presentation of the different tumors. Excess hormones 
circulating in the blood can produce clinical symptoms that can lead to a diagnosis of the 
presence of a specific malignancy [345, 384, 395-399]. Alternately, non-functioning tumors 
do not generate excess hormones and, therefore, remain clinically silent until the tumor mass 
itself becomes a burden or the mass is identified during an unrelated or routine imaging 
procedure [278, 349, 355, 368, 381, 400-403]. Symptoms identified during clinical 
presentation associated with non-functioning tumors include abdominal pain, weight loss, 
fatigue, jaundice, and nausea [289, 359, 381, 404]. 
 The various functioning tumors are indicated by evidence of a pancreatic mass in 
addition to digestive system or neurological symptoms based on the nature and activity of 
the hormone that is over produced in that tumor. The hormone output of these tumors can be 
so significant that symptoms are present while the tumor itself is too small even to be 
detected by diagnostic imaging techniques [405-407]. Diagnosis of functioning tumors after 
a clinical presentation of symptoms requires a measurement of hormone levels in the blood 
[367, 399, 408].  
 Insulinomas are the most commonly diagnosed functioning pancreatic NET, the 
majority of which are classified as benign tumors [365, 409]. Insulinomas present clinically 
with symptoms of hypoglycemia because excess circulating insulin leads to sequestering of 
glucose and a corresponding neurological impairment in function indicated by confusion, 
disorientation, sweating, and, potentially, loss of consciousness [365, 409-415]. Diagnosing 
insulinomas requires an analysis of the component diagnostic factors of Whipple’s triad: 
plasma glucose level less than 2.5 mmol/L (45 mg/dL), neuroglyopenia, and symptomatic 
relief following glucose administration [380, 416]. Additional criteria have been established, 
including the evaluation of plasma insulin and the connecting peptide (C-peptide), another 
metabolite of the production of insulin from proinsulin [417], levels [365, 418]. A fasting 
test of up to 72 hours can detect abnormal concentrations of both glucose and insulin to 
support the insulinoma diagnosis in up to 100 percent of patients, and is considered the 
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clinical gold standard for diagnosis [413, 414, 418-421].  
 Gastrin-secreting tumors [422-424] are the second most common functioning tumor 
[348]. Gastrinomas typically originate in the duodenum but are also found as primary 
tumors of the pancreas [375, 425-439]. The clinical presentation of gastrinomas typically 
encompasses the symptoms associated with Zollinger-Ellison syndrome [440, 441] due to 
excess circulating gastrin: hyperchlorhydria, peptic ulcer disease, diarrhea, and abdominal 
pain or cramps [375, 425, 438, 439, 442-445]. Fasting gastrin levels, serum gastrin 
evaluation following administration of secretin or calcium, and gastric acid pH are 
diagnostic tests for gastrinoma diagnosis [383, 426, 427, 446-451]. Malignancy is common 
in gastrinomas [436, 439, 452, 453], and about half of patients have lymph node or liver 
metastases at diagnosis [348, 426, 427, 429, 430, 438, 441, 454-457]. Presence or absence of 
liver metastases is the major pathological criterion for survival estimates in these patients 
[382, 430, 434, 455, 458, 459]. Metastasis formation has been correlated with site of the 
primary tumor, with gastrinomas originating in the pancreas behaving more aggressively, 
resulting in poorer prognosis [425, 432, 434, 436]. 
 Glucagonomas arise from the alpha cells of the islets and secrete excess glucagon 
resulting in various symptoms including weight loss, a migrating rash, diabetes, and diarrhea 
[360, 371, 374, 377, 379, 460-464]. Diagnostic criterion requires a fasting blood test for 
glucagon levels [367, 371, 379, 461, 462, 465]. Prognosis with these tumors is dependent on 
the presence or absence of metastases at diagnosis [466]. Liver metastases are commonly 
found at diagnosis [360, 462, 463, 467], significantly decreasing five-year survival odds 
[374, 379, 466]. 
 Somatostatinomas are exceedingly rare [358, 378, 468-470]. Clinical symptoms 
associated with this tumor type are associated with the inhibitory effects of somatostatin on 
other hormones and include hyperglycemia, diabetes mellitus, diarrhea, weight loss, and the 
formation of gallstones, and a diagnosis is possible with evidence of elevated somatostatin 
levels in patients [376, 468, 470-472]. The presence of metastases at diagnosis decreases the 
five-year survival rate dramatically [376], and metastases of the lymph nodes or liver are 
present in half of patients with somatostatinomas [358, 366, 367, 468]. 
 Vasoactive intestinal peptide (VIP) is produced in the central nervous system as well 
as the pancreas and intestine, peripherally, and functions in motility and absorption in the 
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small intestine [473, 474]. About eighty-five percent of VIPomas occur in the pancreas [367, 
373]. These tumors are malignant in half of the cases and are typically diagnosed as 
advanced disease with lymph node or liver metastases present at diagnosis [372, 373]. 
Clinical diagnosis of a VIPoma is based on patients presenting with severe diarrhea [372, 
467, 473] and elevated	  levels of circulating VIP in the blood [367, 475, 476]. This tumor is 
associated with Verner-Morrison syndrome [477, 478], or WDHA syndrome, an acronym 
indicating the presence of watery diarrhea, hypokalemia, and achlorydria [477-481].	  
  Serotonin-secreting functional tumors, historically termed carcinoids, arise from 
enterochromaffin (EC) cells and are rarely found as primary pancreatic lesions [363, 482-
485] but have been increasing in incidence over time [486]. These tumors are typically at an 
advanced stage at diagnosis with a rate of metastasis around 70 percent [363, 482, 483, 485, 
487] and the likelihood of metastatic aggressiveness increasing with an apparently 
corresponding increase in primary tumor size [394]. Carcinoid tumors secreting serotonin 
present with a constellation of symptoms that include flushing episodes, diarrhea, cramps, 
and cardiac abnormalities [487, 488] collectively defined as carcinoid syndrome [489-491]. 
A test for 5-hydroxyindoleacetic acid, a metabolite of serotonin, levels in urine is 
demonstrative of a carcinoid [363, 487].  
 Tumors secreting pancreatic polypeptide (PPomas) do not generally result in clinical 
symptoms associated with hormone production [492, 493]. Therefore, these tumors are 
generally found incidentally or due to the effects of tumor mass or metastases causing 
symptoms [278], resulting in their occasional classification as non-functioning tumors. 
 Comparing patient prognoses reveals a historically conflicted discrepancy in survival 
probability among patients with functioning NETs versus those with non-functioning 
tumors. Significant clinical indications of poor prognosis and decreased survival for patients 
with non-functioning tumors include poor tumor differentiation, lymph node or liver 
metastases at diagnosis, and increased mitotic index [404, 494-496]. The 5-year survival rate 
for patients with non-functioning tumors ranges from around 30 to 70 percent [327, 353, 
355, 361, 402, 403, 497], with at least a third of patients with metastatic disease at diagnosis 
[272, 278, 279, 327, 353, 355, 381, 402, 404, 498-500]. Some studies indicate an increase in 
long-term survival when diagnosed with a functioning tumor compared to a non-functioning 
tumor [273, 277, 329, 348, 353, 357, 466, 497, 501-504]. This can be justified by the lag 
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before diagnosis that occurs with non-functioning tumors lacking the clinically relevant 
symptomatology found in functioning tumors [289, 353, 355, 381, 402, 492, 499]. However, 
though identified as a significant predictor of prognosis at diagnosis [329], functional status 
of pancreatic NETs has been contested as clinically relevant historically [272, 275, 354, 505, 
506]. This could be skewed by multiple sources, including sample size [354, 505-507], the 
prognostic variability among non-functioning tumors [496], or the distinction between 
overall survival and disease-free survival [504]. Generally, though the tumor biology 
remains unchanged between the groups [289], the percent of patients with non-functioning 
tumors diagnosed with advanced disease, either infiltration of regional lymph nodes or 
metastases, is greater than what is found in patients presenting with functioning tumors [348, 
353, 355, 368, 499, 501]. Numerous studies reveal an earlier diagnosis and better overall 
prognosis for patients related to tumor stage at diagnosis [272, 354, 362, 466, 505, 506]. 
Moreover, overall survival drops precipitously with advanced disease at diagnosis 
independent of tumor functional status [270, 272, 273, 329, 357, 466, 508]. 
 Malignant pancreatic NETs most often metastasize to lymph nodes and the liver, but 
bone metastases and lung are also found in some patients [272, 374, 375, 509]. Stage of 
disease at diagnosis and aggressiveness of the tumor are indicators for prognosis [329]. The 
presence or absence of hepatic metastases is significant clinically, because prognosis is 
dramatically reduced in patients with disease advanced to the liver [270, 272-275, 278, 279, 
354, 404, 466, 483, 492, 497, 501, 502, 506-508, 510, 511]. With no evidence of hepatic 
metastases, survival rates are greater than seventy percent at ten years. However, long-term 
survival drops precipitously when liver metastases are found concurrent with the primary 
tumor [327, 354, 404, 466, 483]. Additionally, the presence of bone metastases is also 
indicative of a poor prognosis with a reduction in patient survival [459, 512]. Less is 
understood regarding the significance of positive lymph node metastases at diagnosis, 
though the majority of studies, but not all, indicate infiltration of lymph nodes is an 
indication of poorer prognosis overall [270, 272, 278, 327, 359, 404, 434, 466, 494, 506, 
507, 510, 513-515].  
 In addition to tumor stage and functional status, prognosis of all pancreatic NETs is 
also affected by tumor size, differentiation, mitotic index, degree of necrosis, location within 
the pancreas, age of the patient at diagnosis, treatment susceptibility, and the presence or 
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absence of a genetic syndrome associated with tumor formation [270, 273, 274, 339, 421, 
458, 466, 502, 506, 516-520]. The most common genetic syndrome found in NETs of the 
pancreas is multiple endocrine neoplasia type 1 [392, 521, 522]. 
 
 
MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 
 
 Pancreatic NETs can be sporadic or associated with an inherited disorder. Genetic 
diseases that have a pancreatic component include multiple endocrine neoplasia type 1 
(MEN1) syndrome, von Hippel-Lindau (VHL) disease, and neurofibromatosis type 1 (NF-1) 
[521-525]. VHL syndrome involves tumors in multiple organs including manifesting as 
cysts or adenomas of the exocrine pancreas or non-functioning endocrine tumors in 15 to 25 
percent of patients [526-533], while NF-1 syndrome can result in somatostatinomas or 
insulinomas of the pancreas in rare cases [366, 376, 534-537]. MEN1, however, has a much 
more common frequency of endocrine tumor formation in the pancreas, with up to ten 
percent of all pancreatic NETs associated with MEN1 and over half of MEN1 patients 
diagnosed with a pancreatic NET [538-542].  
 The constellation of symptoms and tumors first described by Wermer in 1954 
eventually came to be identified as MEN1 [543, 544]. MEN1 syndrome is an autosomal 
dominant disease that results in tumors of the parathyroid, pituitary, foregut, adrenocortical 
glands, as well as the endocrine pancreas [521, 538, 541, 542, 545-549]. Classically 
presenting MEN1 patients have tumors in at least two of three common sites, typically the 
endocrine pancreas, the pituitary, or the parathyroid [538, 539, 541, 549-553]. The 
prevalence of MEN1 syndrome ranges from two to 20 individuals of every 100,000 [539]. 
 MEN1 syndrome results from the loss of MEN1 tumor suppressor gene function 
following Knudson’s two-hit hypothesis [554-557]. The MEN1 gene is located on 
chromosome 11q13 and encodes the protein menin from ten exons [558-564]. Menin, a 
nuclear protein [565-567], is expressed ubiquitously [568-571] and acts a tumor suppressor 
with roles in DNA repair [572-574] as well as cell proliferation and transcription regulation 
[575-585]. Studies of familial MEN1 disease reveal germline mutations in up to 90 percent 
of cases, with additional mutations probable outside the studied region [538, 550, 551, 586-
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592]. The mutations, consisting of nonsense and missense mutations as well as insertions 
and deletions, occur in multiple exons and typically alter the amino acid sequence of menin, 
resulting in loss of protein function [586-589, 593-597]. Loss of heterozygosity and 
epigenetic studies reveal alternative mechanisms of silencing the MEN1 gene in these 
patients [389, 540, 558, 562, 598-605]. Differential expression analysis reveals a complete 
lack on menin expression in MEN1 tumors, while sporadic pancreatic NETs and tissue from 
non-tumor associated endocrine and exocrine pancreas retain menin expression [567], 
confirming loss of protein function in the MEN1 tumors. 
 Multiple pancreatic NETs are associated with MEN1 syndrome [553]. MEN1 
syndrome can result in numerous small tumors, functioning and non-functioning, located 
throughout the pancreas [425, 551, 606-611]. The frequency of tumor types in MEN1 
patients is widely variable with non-functioning tumors, insulinomas, and gastrinomas the 
most commonly occurring, while somatostatinomas, glucagonomas, VIPomas, and carcinoid 
tumors are found less often in these patients [538-541, 545, 547, 552, 592, 607, 608, 612-
616]. About five percent of total insulinoma and twenty-five percent of gastrinoma 
diagnoses are related to MEN1 syndrome [375, 418, 425-427, 436, 442, 445, 617-619]. 
Interestingly, MEN1 associated tumors can vary in both number and size compared to the 
same tumor type as a sporadic tumor. Noticeably distinct from sporadic insulinomas that 
present as solitary tumors, insulinomas associated with MEN1 syndrome occur as 
multicentric tumors, and, commonly, are linked to disease recurrence over time [369, 418, 
539, 620-622]. Gastrinomas arising in MEN1 patients typically localize to the duodenum, 
while pancreatic gastrinomas associated with MEN1 syndrome are occasionally found [439, 
608, 617, 623-625], but these tumors, like insulinomas in MEN1 syndrome, often occur as 
multiple, small tumors rather than isolated single tumors typical of sporadic cases [425, 439, 
599, 610, 617, 625, 626]. Up to half of MEN1-associated gastrinomas are found as 
metastatic tumors [425, 429, 607, 617] corresponding with a poor prognosis [458]. In 
addition to insulinomas and gastrinomas, VIPomas are occasionally found in patients with 
MEN1 syndrome, while other functioning pancreatic NETs are exceedingly rare in 
association with MEN1 disease [606]. Alternatively, non-functioning tumors occur in about 
half of MEN1 patients [609].  
 Malignant pancreatic NETs, and the associated symptoms, are commonly the cause of 
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death in patients with MEN1 syndrome [546, 613, 627-629]. To combat this, primary tumors 
identified in MEN1 kindreds under surveillance are resected to limit, or delay, formation of 
hepatic metastases [630]. Additionally, the early age at which tumors occur in MEN1 
patients requires diligence in imaging studies and clinical assessment of circulating 
hormones to identify primary tumors [541, 610, 631]. Genetic testing for Men1 mutations 
can also identify at-risk MEN1 patients requiring more stringent or frequent biochemical or 
imaging analyses than otherwise warranted [632]. This is a long-term requirement as 
recurrence or further disease manifestation is also common in MEN1 patients [538, 632-
634]. In addition to the familial MEN1 syndrome, loss of heterozygosity, mutation, or other 
loss of function of the MEN1 gene has been found in up to 40 percent of sporadic NETs of 
the pancreas [562, 594, 635-644], totaling more than a thousand different mutations in 
MEN1 identified in both sporadic and familial cases of pancreatic NETs [356, 540, 556, 560, 
586, 588, 592, 594, 595, 597, 615, 636-640, 642-647]. 
 
 
SOMATOSTATIN AND SOMATOSTATIN ANALOGS 
 
 Consistent with other tumors with a hormonal component, NETs, and pancreatic NETs 
specifically, overexpress receptors related to hormonal homeostasis and regulation. Tumors 
express these receptors inconsistently and variably, but the majority of pancreatic NETs 
overexpress somatostatin receptors (SSTRs) generally, and somatostatin receptor type 2 
(SSTR2) specifically [41-49, 51, 648-650]. 
 SSTRs are G-protein coupled receptor family members distributed throughout the 
gastrointestinal tract and the nervous system [49, 651-655]. The five known SSTRs (SSTR1 
through SSTR5) are distributed in variable concentrations throughout the body [656-666]. 
SSTR2, however, is consistently found in around 80 percent of pancreatic NETs [41, 45, 
650, 667-673], making it susceptible to ligand-directed therapeutic agents [674, 675]. 
Tumor-type specific analysis of SSTR2, reveals that greater than eighty percent of 
gastrinomas, glucagonomas, and somatostatinomas, in addition to half of insulinomas, are 
positive for SSTR2 expression, characterized as both dense and homogeneous in tumors 
positive for expression [45, 457, 649, 669, 673, 676-678]. This could be due to the variable 
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activity of the SSTR subtypes mediating different physiological activity. Specifically, as 
opposed to other pancreatic peptide hormones, SSTR5, and not SSTR2, mediates insulin 
activity in the pancreas [679-683].  
 Somatostatin, first identified as a powerful inhibitor of various hormones, was initially 
named accordingly and has been termed growth hormone-inhibiting hormone (GHIH), 
somatotropin release-inhibiting factor (SRIF), or somatotropin release-inhibiting hormone 
(SRIH) historically [38, 684]. Physiological activities of somatostatin include inhibitory 
actions against insulin and glucagon from the pancreatic islets [685-700], growth hormone 
(GH) and thyroid stimulating hormone (TSH) in the pituitary gland [38, 695-697, 701-705], 
and various other gastrointestinal hormones including gastrin, secretin, motilin, and 
vasoactive intestinal peptide (VIP) [39, 686, 699, 706, 707]. In addition to physiological 
activities of somatostatin, regulatory roles in pathological conditions have also been 
described [39, 700]. 	   Somatostatin is produced in islets of the pancreas, stomach, and intestines as well as 
the central nervous system, including the hypothalamus [71, 75, 700, 705, 708, 709]. There 
are two known forms of somatostatin, a 28 amino acid peptide and a 14 amino acid peptide, 
derived from a somatostatin pro-hormone [710-716], in response to glucose, lipids, amino 
acids and circulating hormone levels [39, 717, 718]. Somatostatin also inhibits cellular 
proliferation, demonstrating further utility as an oncologic agent [719, 720]. Somatostatin 
binds all of the SSTRs with affinities in the nanomolar range [721-723], initiating signal 
transduction cascades through multiple pathways depending on the cell type expressing the 
receptors. Binding the G-protein coupled receptors of the neurons initiates potassium (K+) 
channel activity and decreases calcium (Ca2+) channel function, keeping the channel closed 
to hormones exiting the cells [724-727]. Receptor internalization upon ligand binding occurs 
with SSTRs dependent on the length of exposure to the ligands in circulation as well as the 
total ligand concentration [728-733]. 
Somatostatin administration to various species, including human, reveals minimal 
toxicity, and inhibitory effects observable within the fifteen minutes following 
administration, supporting clinical applications [734]. There are at least five cleavage sites 
within the length of the 14 amino acids of somatostatin [735], and, as a result, endogenous 
somatostatin has a circulating half-life of around 2 minutes [50, 736], making it ineffective 
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for clinical applications and requiring synthetic analogs be used instead [51, 737, 738]. 
Studies identified the beta-turn region encoded by the four amino acid sequence Phe-Trp-
Lys-Thr (FWKT) as the minimal region necessary for biologic activity [739-741], 
encouraging the development of numerous peptide analogs of somatostatin with this 
knowledge in mind. Compounds have been synthesized with varying modifications and 
amino acid substitutions outside of this four amino acid region and analyzed for their ability 
to recapitulate biological activity and physiological inhibitory functions [52, 727, 739-752]. 
 Peptide analogs are designed to resist circulating proteases. In the case of somatostatin 
analogs specifically, this allows the manufactured analogs to have an increased half-life in 
circulation while mimicking the pharmacological activity of somatostatin itself, providing a 
clinically relevant avenue for tumor targeting [753]. Octreotide (amino acid sequence 
FCFWKTCT) is one such synthetic somatostatin analog [52]. Octreotide is a cyclic 
octapeptide with a 90-minute half-life in circulation [52, 53]. This peptide, originally termed 
SMS 201-995, is marketed clinically in the salt form octreotide acetate, and is identified as 
Sandostatin. Octreotide binds preferentially to SSTR2, with binding to SSTR3 AND SSTR5 
observed to a lesser extent [656, 722, 727, 749, 754-756], encouraging its use in the 
treatment of pancreatic NETs consistently overexpressing SSTR2 [735, 757]. A long acting 
form of octreotide is released into the circulation over a couple of weeks, rather than hours, 
following a single intra-muscular injection [758-760], allowing much fewer administrations 
than the original formulation.  
 The octreotide peptide has been thoroughly evaluated for the ability to recapitulate 
the biological activity of the native somatostatin peptide [53, 735]. Effective inhibition of 
growth hormone, insulin, and glucagon secretion in rodent, non-human primates, and 
humans was observed early on in the evaluation of the peptide for clinical utility and 
encouraged speculation that octreotide would be effective in the treatment of disorders 
associated with hormone deregulation clinically [52, 212, 761-770]. Administration of 
octreotide also dramatically reduces islet blood flow specifically, while total blood flow to 
the pancreas remains unchanged [212], tangentially supporting the physiological inhibitory 
properties of somatostatin and its analogs by limiting the accessibility of circulating 
hormones, and to the alpha and beta cells of the islets, and, therefore, limiting the 
corresponding stimulation and hormonal release in response. Oncological applications of 
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somatostatin analogs were quickly identified [763, 771-782], and early efficacy and toxicity 
trials revealed clinical efficacy with limited toxicity and minimal side effects in patients 
[774, 783-786] including those with pancreatic NETs [763, 765, 785, 787-790].	  
 
  
IMAGING NEUROENDOCRINE TUMORS OF THE PANCREAS 
Definitive tumor detection, localization, and staging for all pancreatic NETs, 
functioning and non-functioning, requires a combination of imaging techniques with varying 
specificity and sensitivity [791-795], including ultrasound, computed tomography (CT), 
magnetic resonance imaging (MRI), positron emission tomography (PET), and somatostatin 
receptor scintigraphy (SRS). CT and ultrasound can be useful for tumors larger than two 
centimeters in diameter. There are greater limitations on tumors with a diameter less than 
five millimeters, however, limiting the utility of these imaging techniques for some 
functioning tumors. The typically small size of these tumors makes localization difficult and 
supports with use of multiple imaging studies for definitive assessment of tumors [796-798]. 
Ultrasound imaging, including transabdominal and endoscopic ultrasonography, vary 
in sensitivity, but both techniques are generally able to detect tumors greater than three 
centimeters in size [796-799]. Endoscopic ultrasounds possess greater sensitivity and can 
detect small tumors in most cases [293, 631, 800-814]. Endoscopic ultrasonography can also 
determine the status of lymph node metastases [798, 808], and combining needle biopsy 
with endoscopic ultrasound enables tumor localization and staging [804, 813, 815]. 
Limitations to ultrasound imaging for the evaluation of pancreatic NET are due to tumor 
location in the pancreas and the size of the tumor mass [810, 816].  
 CT is critical for pre-operative tumor localization with its ability to distinguish 
various soft tissues providing precise anatomical localization of the tumor within various 
organs. Therefore, CT imaging is widely used for detection of pancreatic NETs [817, 818]. 
Its sensitivity is variable among pancreatic NET subtypes. Insulinomas and gastrinomas, for 
example, have a detection rate of around 60 to 80 percent with CT in multiple studies [405, 
410, 416, 418, 810, 819-824]. CT sensitivity is increased for large tumors and hypervascular 
tumors, both of which allow accumulation of the contrast agent within the tumor for visual 
enhancement [793, 825-827]. Success with CT is enhanced with combination with another 
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imaging modality [823, 828]. For example, combining ultrasound and CT increases 
sensitivity significantly [810, 826]. 
 MRI is incredibly sensitive for identifying single and multiple primary pancreatic 
NETs as well as secondary tumors of the lymph node and liver [406, 818, 821, 829-834]. 
MRI for the detection of liver metastases from multiple NET primary sites, including 
pancreas, reveals a sensitivity greater than eighty percent, with an emphasis on the ability to 
detect primary tumors and metastases that are small in size [831-833, 835-837]. 
PET imaging uses radiolabeled tracers to evaluate metabolism and cellular uptake in 
tumors, and, therefore, is beneficial for detection of primary and metastatic pancreatic NETs 
[838-842]. Due to the nature of cells of the endocrine system and their facilitation of amine 
precursor uptake and decarboxylation [843-846], alternative tracers, including fluorine-18 
(18F)- or carbon-11 (11C)-labeled L-3,4-dihydroxyphenylalanine (L-DOPA) and 11C-labeled 
5-hydroxy-L-tryptophan (5-HTP) are superior to traditional 2-(18F)-fluoro-2-deoxy-D-
glucose (18F-FDG) to evaluate uptake and metabolic activity for use as a radiotracer for 
imaging functioning NETs of various organs [840, 844, 847-851], including the pancreas 
[828, 838-841, 852, 853]. Nonfunctioning, highly proliferative, and poorly differentiated 
tumors, however, can retain a more traditional metabolism supporting identification with 
18F-FDG PET scans [854-858]. In addition, PET imaging using labeled somatostatin 
analogs, including octreotide, is also effective for localizing pancreatic NETs with superior 
sensitivity for both primary and secondary tumors sites [857, 859-866]. Size, tumor 
differentiation status, and functional status of tumors determine the applicability of PET 
imaging studies, with the majority of functioning tumors especially susceptible to PET 
imaging [842, 847, 852, 865]. PET can also be used to monitor tumor response to treatment 
over time, especially in functional tumors [840, 853, 859]. 
 Radioactive octreotide is also used clinically for both diagnosing and localizing 
somatostatin-sensitive tumors [867-874]. This procedure, called somatostatin receptor 
scintigraphy (SRS) and marketed as the OctreoScan, allows clinicians to visualize 
radiolabeled octreotide accumulated in tumors to identify both primary or metastatic tumor 
sites overexpressing somatostatin receptors [484, 672, 794, 809, 856, 871, 875-880]. SRS 
utilizes octreotide or another somatostatin analog conjugated to a radioisotope, commonly 









avid tumors after a scintigraphy scan with both high sensitivity and specificity [672, 794, 
864, 875, 876, 885-891].  
 Because both primary and metastatic tumor sites express SSTR2, SRS can localize 
primary and secondary tumor lesions (Table 2) [648, 677, 792, 823, 835, 847, 856, 869, 
877, 883, 892-897]. Insulinomas, compared to other pancreatic NETs, express low levels of 
SSTR2, making SRS less effective for diagnostic and localization studies, requiring the use 
of other imaging technologies [386, 835, 861, 897, 898]. However, as SSTR2 expression 
levels vary between tumors and patients and increase in malignant or progressing 
insulinomas, SRS cannot be omitted as a potential imaging tool for use in patients with 
insulinomas [45, 365, 649, 672, 899-905]. Alternatively, the remaining pancreatic NET 




tumor (combined) 74 - 92 
Lymph node, 
liver, bone, soft 
tissue  
[828, 856, 864, 
875, 876, 881, 
882] 
Non-functioning tumor 56 - 87 Lymph node, liver, bone [667, 796, 823] 
Insulinoma 13 - 83 Lymph node, liver 
[672, 796, 802, 
809, 823, 847] 
Gastrinoma 61 - 100 Lymph node, liver, bone 
[667, 672, 796, 
809, 823, 883-
885] 
Glucagonoma 95 - 100 Lymph node, liver [360, 667, 672] 
VIPoma 100 Lymph node, liver [667] 
Carcinoid 50 - 91 Lymph node, liver, bone [823, 847, 848] 
Other functioning tumors 57 Lymph node, liver [823] 
Table 2. Effectiveness of SRS for tumor localization in pancreatic NETs  
	  	  
21	  
types express SSTR2 in the vast majority of cases, allowing utilization of SRS for 
localization of primary and metastatic tumor sites associated with these tumors, with 
successful localization correlated with the size of the primary tumor [883, 885, 906]. SRS in 
combination with at least one other diagnostic imaging technique is recommended to fully 
appreciate the extent of disease [386, 672, 792, 816, 869, 876, 884, 893, 907, 908]. Common 
sites of metastases for pancreatic NETs include lymph nodes, liver, and bone [374, 375, 379, 
509]. Liver metastases larger than one or two centimeters [835, 856] and bone metastases 
[830, 856, 864, 885, 909] are visible with SRS. Use of single photon emission computed 
tomography (SPECT) increases the sensitivity of SRS [835, 870, 904, 910], while CT or 
MRI provide additional anatomical information regarding tumor localization. 
Successful localization of tumors varies greatly among different tumor types. [677]. 
The presence of multiple or small tumors, as is sometimes found in MEN1 patients, also 
leads to difficult definitive localization with SRS [911]. Additionally, correctly discerning 
non-functioning pancreatic NETs from pancreatic tumors of exocrine origin is possible 
using SRS, further expanding the diagnostic utility of SRS [381]. Because SRS sensitivity 
corresponds to SSTR2 expression in tumors, a positive SRS scan indicates octreotide-avid 
tumors expressing SSTR2. These tumors are potentially susceptible to treatment with 
somatostatin analogs, including octreotide, making a positive SRS a clinical biomarker [648, 





 Pancreatic NETs typically require a twofold approach in the clinic. In addition to a 
primary curative objective for all patients, relief of symptoms associated with hormone 
hypersecretion is a secondary clinical goal for patients with functioning tumors [269, 486, 
913, 914]. Surgical resection remains the only potentially curative option currently available 
for patients [508, 915-918], but its application is dependent on tumor size, invasiveness, 
location in the pancreas, stage at diagnosis, and whether an inherited syndrome is present 
[334, 466, 493, 507, 916, 917, 919-923]. The surgical approach towards pancreatic NETs 
can compromise enucleation, pancreatic resection, and total pancreatectomy for tumors 
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isolated to the pancreas, with tumor de-bulking, lymph node resection, liver resection, and 
even liver transplantation indicated for advanced disease [269, 327]. 
 Enucleation of the tumor is recommended for small tumors that are isolated from the 
main pancreatic duct [412, 924]. This technique requires concurrent ultrasound imaging to 
locate and guide the surgeon to the tumor. The tumor is removed from the pancreatic tissue 
and any blood vessels associated with the tumor are cut and sutured to limit bleeding [467]. 
This is the most common surgical procedure for removing small, benign insulinomas [365, 
369, 413, 418, 467, 924-926] and other small, resectable tumors [429, 430, 630]. Patients 
presenting with large or multiple tumors generally require resection of the pancreas or even 
the more aggressive total pancreatectomy [504, 620]. The traditional 
pancreatoduodenectomy, or Whipple procedure [927], is indicated for aggressive tumors 
located in the head of the pancreas that have invaded into the duodenum or metastasized to 
the lymph nodes [503, 928, 929]. This surgical procedure has been refined to protect the 
pylorus, the section of the duodenum that emerges from the stomach, called a pylorus-
preserving pancreatoduodenectomy [930, 931], that is indicated for some patients with 
aggressive or invasive tumors in the head of the pancreas [612, 615, 929, 930, 932]. For 
tumors located in the tail of the pancreas a distal pancreatectomy is indicated [429, 924]. 
Patients with multiple tumors, highly aggressive tumors, or MEN1 syndrome sometimes 
require a more aggressive surgical approach including total pancreatectomy [610, 612, 615, 
621, 803, 911, 922, 933, 934]. Though uncommon, malignant insulinomas also require a 
more aggressive surgical intervention compared to the benign tumors that make up the 
majority of diagnoses [364, 416, 935, 936]. The length of disease-free survival after surgical 
pancreatic resection varies widely among patients, but surgical intervention remains the only 
potential curative approach to tumor management [241, 272, 289, 362, 404, 434, 454, 503, 
929, 937]. 
Metastatic disease necessitates greater surgical intervention. Resection of liver 
metastases, in addition to primary tumors, is indicated for better overall prognosis and 
quality of life for patients [272, 279, 349, 402, 498, 935, 938-954]. Limitations of liver 
resection are associated with the degree of tumor dissemination and the number of lobes 
containing metastases [459, 951, 955-958]. Ablation therapies, including 
chemoembolization and radiofrequency ablation, have also been evaluated for their 
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effectiveness in decreasing tumor volume in patients with metastatic disease that is not 
suitable for surgical resection [381, 952, 959-964]. These treatments attempt to either 
destroy the tumor tissue or reduce vascularity in tumors, especially metastases in the liver, 
with radiofrequency ablation, cryotherapy, or injecting alcohol directly into the tumor when 
possible [959, 962]. Patients with diffuse hepatic metastases require a palliative clinical 
approach utilizing tumor de-bulking surgery, chemotherapy, radiotherapy, and peptide 
biotherapy for symptomatic relief and to decrease the tumor burden [421, 935, 942, 965-
973]. Alternatively, reports of liver transplantation have been documented with varying 
results [948, 949, 951, 974-992]. The consensus seems to be that liver transplantation for 
patients with un-resectable liver metastases is a viable option, but limited donor organs 
requires careful assessment of the patient and tumor and overall caution with proceeding 
[948, 977, 983-986, 988-991, 993-995].  
 Since curative surgery is not always possible, some patients require alternative or 
supplemental treatment to suppress tumor growth or relieve symptoms manifesting from 
functioning tumor hypersecretion. The course of treatment is dependent on tumor 
aggressiveness and can vary from a “wait and see” approach for non-growing or slow-
growing tumors to aggressive chemotherapy and radiotherapy treatments. Additionally, 
biotherapy with somatostatin analogs is recommended as a single-agent therapy or in 
combination with other agents to manage symptoms associated with functioning tumors 
[336, 996].  
Somatostatin analogs, and specifically octreotide, are useful for treating symptoms 
associated with functioning pancreatic NETs due to their ability to both inhibit hormone 
secretion and stabilize tumor growth [51, 759, 771, 915, 997-1004]. Biotherapy with 
somatostatin analogs is particularly useful clinically because of the limited, and generally 
minimal, side effects associated with therapy as well as an increase in overall patient quality 
of life in regards to symptomatic relief of hormone hypersecretion [785, 788, 789, 997-1000, 
1005-1017]. The clinical significance of octreotide and other somatostatin analogs as 
antiproliferative therapeutics are variable, but these agents are potentially effective in a 
subset of patients with advanced or progressing disease at diagnosis [996, 998, 1002, 1004, 
1005, 1016, 1018-1024]. Isolated and sporadic occurrences of effective tumor shrinkage in 
these reports could be due to apoptosis induction in tumor cells specifically with 
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somatostatin analog therapy at high doses [723, 1003, 1025-1031], although others show no 
such benefit associated with somatostatin analog treatment related to tumor response. 
 Somatostatin analogs mimic the biological activity of somatostatin itself, limiting 
their utility in the treatment of benign insulinomas, but enabling symptomatic relief in other 
tumor types. Somatostatin is considered an inhibitory hormone, suppressing the release of 
gastrointestinal hormones including glucagon, gastrin, and VIP, supporting its effectiveness 
in the relief of symptoms associated with tumors secreting the corresponding hormones. 
However, as glucagon acts to lower blood glucose levels, somatostatin analogs can 
exacerbate neuroglucopenia in insulinoma patients. Accordingly, insulinomas have a 
variable response to octreotide biotherapy dependent on somatostatin receptor expression in 
the tumors [901, 1032], but alternative therapeutic options, including the utility of diazoxide, 
known to inhibit insulin secretion [1033], have been studied in these patients [1034, 1035]. 
 Sandostatin, the brand name of the octreotide salt and long-acting formulations 
distributed by Novartis Pharmaceuticals, has been approved by the United States Food and 
Drug Administration (FDA) for the treatment of watery diarrhea associated with VIPomas 
[481] and flushing episodes related to carcinoid syndrome [758, 1036]. It is also used off-
label for treatment of symptoms associated with other functioning tumors, including 
erythema and anorexia from glucagonomas [462] as well as chemotherapy-induced and 
other pathologic diarrhea [1037, 1038]. Symptomatic relief of hormone secretion in response 
to somatostatin analog therapy has been observed in patients with functioning tumors, but 
tumor growth inhibition has been suggested but not definitively supported by studies in 
patients [723, 759, 998-1000, 1004, 1039-1044]. Side effects associated with somatostatin 
analog therapy typically lessen overtime and include gastrointestinal discomfort, abdominal 
pain, steatorrhea, and nausea [51, 788, 970, 1009, 1045]. Somatostatin analog therapy is also 
used in conjunction with surgical procedures, with an octreotide regimen initiated in patients 
prior to and following surgery to limit the possibility of a hormonal surge in response to 
surgery creating a metabolic crisis [51, 467, 962]. 
 The usefulness of chemotherapy is dependent on individual tumor characteristics and 
the effectiveness of alternative therapies [915, 962, 1046, 1047]. Chemotherapeutics in 
pancreatic NETs are used clinically in a couple of tumor types. Etoposide and cisplatin are 
used to treat some fast growing, poorly differentiated tumors [962, 1048-1051], while 
	  	  
25	  
streptozotocin alone or in combination with either doxorubicin or 5-fluorouracil have been 
effective in treating some well differentiated tumors [936, 1052-1055]. However, tumors of 
endocrine origin are generally resistant to chemotherapy, and variable responses to treatment 
are seen in tumors with similar histological profiles [962, 1046, 1056-1058]. Specifically, 
some malignant insulinomas and VIPomas are responsive to chemotherapy [936, 1052, 
1053, 1059-1061] while other tumor types have not had significant clinical responses to 
chemotherapy studies [421, 962, 1046, 1062]. However, the variability of response rates 
among different agents and tumor types indicates chemotherapy cannot be excluded as a 
potential treatment option for any tumor type [1056, 1063]. Additionally, symptoms and side 
effects commonly associated with chemotherapy are consistently observed in these trials and 
should be weighed in consideration of patient quality of life concerns [1046, 1048, 1055, 
1056, 1062].  
 Interferon alpha is effective for the treatment of pancreatic NETs, and specifically a 
viable therapeutic option for tumors negative in an SRS scan indicating a lack of SSTR2 
expression for peptide-targeting biotherapy [1060, 1064-1066]. Significant side effects and a 
decreased overall quality of life are occasionally observed with interferon alpha therapy 
[1060, 1066]. 
 Targeted delivery of radiation directly to tumors is also being studied. This 
technique, called peptide receptor radionuclide therapy (PRRT), requires conjugation of a 
radioisotope to somatostatin analogs [1067] to deliver radiation directly to octreotide-avid 
tumor cells [870, 1068, 1069]. Once within the cells, radionuclides are capable of delivering 
a much higher dose of radiation than traditional external beam radiation. Studies using this 
strategy, specifically yttrium-90 (90Y) and lutetium-177 (177Lu) radionuclides conjugated to 
octreotide or another somatostatin analog called lanreotide, have been evaluated for efficacy 
and toxicity in patients [1068, 1070-1082]. The few studies available have shown disease 
regression and increases in both progression-free survival and overall survival in patients 
treated with PRRT [905, 965, 1068, 1071, 1076, 1080, 1083, 1084]. However, an extensive 
toxicity profile with side effects to bone marrow, kidney, and liver were observed, requiring 
dosage manipulations, co-injections with protective amino acid or gelatin solutions, and 
monitoring physiologic function for changes after administration [960, 1068, 1069, 1071-
1073, 1077, 1078, 1080, 1083, 1085-1090].  
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 Novel clinical biomarkers and their corresponding derivative drug candidates are 
being identified and evaluated for anti-tumor activity in NETs [1091-1101]. Additionally, 
agents that function as inhibitors against receptors common in tumors, including agents 
active against markers of angiogenesis and tumor progression, are also being evaluated 
clinically for their utility as therapeutic agents in pancreatic NETS in patient trials [486, 918, 
1102-1106]. For example, the efficacy of everolimus, an inhibitor of mTOR activity 
previously evaluated for the treatment of renal cell carcinoma [1107-1109], was shown in 
large, multi-center clinical trials for the treatment of pancreatic and other NETs [1110-
1113]. Recently, the FDA approved everolimus, marketed as Afinitor, for the treatment of 
advanced pancreatic NETs1. Everolimus is capable of suppressing the activity of the 
mammalian target of rapamycin (mTOR) protein, and, therefore, eliminating the cell growth 
and corresponding tumor progression associated with activation of the mTOR signaling 
pathway [676, 1114-1118]. Furthermore, another agent, sunitinib, has also been studied in 
recent clinical trials for efficacy in patients with advanced disease [1102, 1119-1121]. 
Studies with this drug, known to inhibit receptor tyrosine kinases, including vascular 
endothelial growth factor (VEGF) family receptors, associated with tumor angiogenesis and 
cell proliferation [1122, 1123], reveal effectiveness as an anti-tumor therapy [1119], with 
limited side effects observed in patients [1120]. FDA approval for sunitinib2 for the 
treatment of progressive disease and well-differentiated pancreatic NETs came just two 
weeks after the approval of everolimus for the same patient population, indicating the 
interest in, and the importance of, identifying therapeutic agents for this patient population 
with limited treatment options (Table 3). 
 Additionally combinatorial approaches have been studied using somatostatin analogs 
with other agents including interferon-alpha [881, 882, 1040, 1066, 1124-1126], 
chemotherapy [1127, 1128], and mTOR inhibitors [1110, 1111, 1113]. Effectiveness of 
combinatorial octreotide and interferon alpha is variable and affected by tumor status at the 
initiation of treatment as well as tumor susceptibility to the agents [882, 1124]. However, 
direct comparisons between combinatorial therapies and octreotide monotherapy reveal a 






adverse symptoms associated with the non-octreotide agent in the combination that is not 
observed in the octreotide treatment group alone [1111, 1124]. This side effect profile was 
confirmed with alternative somatostatin analog combinatorial therapy trials [1040]. 
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Table 3. FDA approved drugs for the treatment of pancreatic NETs 	  






(Zanosar) Chemotherapy 1982 
Metastatic pancreatic 
NET 
Octreotide (Sandostatin) Biotherapy (somatostatin analog) 1998 
VIPoma 
Carcinoid syndrome 
Everolimus 	  (Afinitor) mTOR inhibitor 2011 Unresectable, locally advanced, or metastatic 
pancreatic NET 
Sunitinib (Sutent) Receptor tyrosine kinase inhibitor 2011 
Unresectable, locally 







 With the goal of identifying a candidate biologically active peptide for evaluation in a 
novel manner in the phage display system, the octreotide/SSTR2 ligand/receptor appears to 
be appropriate. As described in the previous section, SSTR2 is known to be overexpressed 
in pancreatic NETs, providing a candidate receptor to exploit on the cell surface. The 
somatostatin analog octreotide has a specific affinity for SSTR2 and is already used 
clinically with much regard for its utility, confirming its appropriateness for use as our 
ligand. Finally, although pancreatic NETs are very rare, there are very limited therapeutic 
options for these tumors, indicating an unmet clinical need for continued investigation into 
potentially useful therapeutic agents in this tumor type. 
 The profile of receptors displayed on the cell surface of NETs provides a basis for 
molecular targeting of these tumors specifically. SSTR2 expression is already used clinically 
for pancreatic NET localization and tumor staging. SRS imaging with somatostatin analog 
targeted delivery of radioisotopes for imaging is a clinical diagnostic standard for tumors of 
neuroendocrine origin [856, 1129]. Displaying a somatostatin analog capable of targeting 
SSTR2 in a phage construct should allow us to recapitulate the binding profile observed in 
the parent peptide. Furthermore, by utilizing an adeno-associated virus and phage hybrid 
(AAVP), the SSTR2-targeting AAVP should be able to deliver a therapeutic reporter gene 
directly to the tumor cells for activity.  
 AAVP is one example of a viral gene-delivery system. Driessen et al. describe 
requirements for a successful targeted gene-delivery system [1130]. The subset of these 
requirements regarding cellular transduction capabilities and transgene expression can be 
met by the use of adeno-associated virus (AAV) with its utility as a gene transfer vehicle 
[1131]. Additionally, vector stability has long been proven for the phage viral particle. The 
other requirements are based on the receptor profile expression and appropriate ligand 
selection or identification. The necessity of receptor expression that is both accessible for 
systemic targeting and specific for target cells is consistent with selective targeting 
approaches, generally, and targeted cancer treatment, specifically [1132]. In the case of 
pancreatic NETs, SSTR2 expression is found in around 80 percent of tumors, described 
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thoroughly in the previous section, which is already being exploited for clinical studies with 
SRS imaging standard for clinical diagnosis and staging of disease. The last general 
necessity for a successful ligand-directed gene-delivery system is appropriate ligand 
selection. The octreotide peptide ligand was rationally chosen as a well-studied and 
reasonable ligand for targeted delivery to NETs of the pancreas to address an under-met 
need in patients with these tumors. Furthermore, continued advocacy for further clinical 
applications directed by or in combination with octreotide or other somatostatin analogs 
indicates a clinical interest in the identification of alternative approaches using these 
peptides [727, 735, 754, 1133, 1134].  
 Any gene-delivery system must be carefully designed for optimal therapeutic benefit. 
Incorporating a targeting ligand for display on the viral particle of AAVP allows cells 
expressing receptors of interest to be specifically targeted. Historically, the use of phage 
libraries required displaying peptides within a specific conformational constraint in the gene 
for the pIII coat protein, either linear peptides (Xn) up to about 30 amino acids, cyclic 
peptides with a conformation of CXnC, or other engineered amino acid formations and 
consensus motifs [12]. These libraries are then administered to receptors of interest, 
monoclonal antibodies, isolated cells or cell lines, in vivo to normal or tumor-bearing 
animals, or even patients and then recovered and evaluated to determine which peptide 
ligand bound what receptor. After identification of a ligand/receptor pair, this new 
knowledge can then be translated into generation of peptides conjugated to clinical agents, 
or targeted imaging or cytotoxic gene therapy agents. To further understand the activity of 
these ligand/receptor pairs, new information is gained concerning receptor localization or 
receptor expression patterns in normal and tumor vasculature to further expand the human 
vascular map.  
 However, to date, no studies have shown that peptides with a known biological 
activity could function in a phage system. Typically, peptide analogs, as is the case with 
somatostatin, are evaluated to determine binding affinity and the ability to evade protease 
activity in circulation, thereby extending their circulating half-life and increasing their utility 
as therapeutic agents. Tumor cells overexpressing specific receptors have been exploited for 
targeted drug delivery, but none of these approaches involve a gene therapy approach for 
therapeutic drug delivery with a biologically active peptide known to have specific 
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functionality within the tumor type. Therefore, generation of an AAVP targeted with a 
known peptide modifying the traditional laboratory protocol [1135], but rather than library 
production, incorporating a sequence encoding a specific amino acid sequence into the pIII 
gene for display on the viral coat protein, should produce a viral particle capable of 
mimicking the activity of the parental peptide and provide the means for targeted delivery of 
a therapeutic gene specifically to the corresponding receptor of this peptide. Specifically, 
exploiting the known overexpression of a receptor on tumor cells by incorporating targeting 
an AAVP particle with the corresponding peptide ligand should effectively enable tumor 
targeting without first identifying candidate ligand/receptor pairs. In our study, generation of 
an AAVP targeted by the octreotide peptide should allow for specific binding and 
localization to tumor cells overexpressing SSTR2 in vitro and in vivo. This octreotide-
targeted AAVP engineered to deliver the gene for tumor necrosis factor (TNF) should 
enable transduction of tumor cells, integration of the TNF gene into cellular DNA, and 
translation of TNF for activity within the tumor itself. In this case, TNF acts as a reporter 
gene, measureable by protein- and RNA-specific quantification techniques. 
 To evaluate AAVP constructs targeting SSTR2 and delivering TNF, we will use the 
Men1 transgenic mouse model. This conditional knockout model forms functioning tumors 
of the endocrine pancreas, recapitulating human disease development and progression. Upon 
successful completion of these studies, we will have generated a pancreatic NET cell-
specific gene therapy vector with an origin in a known ligand/receptor pair. This AAVP will 
be specific for pancreatic NETs with confirmed SSTR2 expression and octreotide avidity 
and will be studied using a well defined and relevant preclinical transgenic mouse model. 
Validation of our AAVP could yield clinical opportunities that could be incorporated into 
the current, established clinical repertoire available to patients with pancreatic NETs, 
providing a new possibility for pancreatic NET management or treatment. 
 
 
ADENO-ASSOCIATED VIRUS AND PHAGE (AAVP) 
 
 Phage has long been regarded as an incredible tool for discovering new ligand/receptor 
pairs and mapping the mouse [30, 31, 35, 1136-1141] and human vasculatures [1142, 1143], 
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in addition to tumor-specific vasculatures [11, 14, 20, 36, 298, 1144-1148]. Phage also 
provides an opportunity to evaluate discrete alterations in a specific model of disease, such 
as the pre-metastatic niche and organotropism in mouse models of tumor metastases [1149, 
1150], and DNA damage repair pathways found in the tumor microenvironment [1151].  
 The clinical usefulness of phage itself is debatable. For research, phage display is a 
technology that is easily modifiable and relativity cheap, but is a powerful tool for 
evaluating ligand/receptor interactions for targeted drug delivery [1152-1155]. After 
administration of a phage, the bound phage particles can then be recovered and evaluated to 
determine the ligand and its candidate receptor [30, 1138, 1156]. This tested and true 
functional activity has allowed a prolific expansion of the understanding of normal and 
tumor vasculature, even in humans, having been studied in terminal patients on life-support 
[1142, 1143]. Additionally, the use of phage historically as an antibiotic agent is providing 
an argument for a resurgent advocacy of the utility of phage as a clinical counter measure to 
overcome bacterial resistance [1157, 1158], further supporting the appropriateness of using a 
phage-based therapy approach in patients. Specifically, the maintenance of a single, 
complete, known genome consistently confirmed and maintained, should overcome the 
disinclination or avoidance of regulatory agencies to approve the native phage as 
“druggable” for the treatment of human diseases [1157]. Evaluation and characterization of 
ligand/receptor pairs identified in phage library screenings is an effective avenue for drug 
development [1140, 1159, 1160]. In addition to indentifying small peptidomimetics that can 
function as drugs [1161, 1162], conjugating peptide mimetics of identified ligands to various 
therapeutic agents allows for targeted drug delivery to the known receptors displayed in the 
tumor or disease state. For example, peptide ligands have been prepared for delivery of 
chemotherapeutics [14, 36], proapoptotic domains [22, 1136, 1140, 1159, 1163-1165], 
cytokines [1166-1168], and genes [1169, 1170] as anti-cancer agents in addition to targeted 
delivery of fluorophores [1171-1173] for imaging. 
 AAVP is a ligand-directed viral particle capable of targeted drug delivery formed from 
the combination of two unrelated genetic systems [1174-1176]. AAVP increases the utility 
of phage alone as a targeting agent by creating a hybrid viral genome of adeno-associated 
virus (AAV) and phage to enable cellular transduction and reporter gene expression. By 
combining the most advantageous components of both prokaryotic phage and eukaryotic 
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AAV, the beneficial aspects of each can be utilized in the new particle [1131]. Phage is a 
consistently effective targeting agent as it is easily modifiable for the introduction of 
targeting peptides in the pIII coat protein [6]. Additionally, the generation of peptides 
requiring a specific conformational constraint, as is the case with the cyclization of the 
octreotide peptide sequence, displayed in the pIII minor coat protein is possible, ensuring 
recapitulation of the functional activity of the native peptide [1177]. However, phage alone 
is unable to efficiently deliver a gene to mammalian cells [1178]. Its activity is restricted to 
receptor binding and induction of any receptor-mediated signaling pathways. AAV, 
alternatively, has no native targeting capabilities and is not easily altered for such ligand-
directed mechanisms [1179]. However, the transduction capabilities of AAV are 
unquestionable with well-described mechanisms of transgene delivery and cellular 
transduction [1180, 1181]. The limitations of both phage and AAV are overcome by 
combining the ligand-directed targeting capabilities of prokaryotic phage and the superior 
transduction capabilities of eukaryotic AAV. The resulting hybrid vector, AAVP, is capable 
of specific homing and mammalian cell transduction for transgene delivery [1174-1176, 
1182-1184]. Inclusion of AAV inverted terminal repeat (ITR) sequences enables integration 
of the gene into the mammalian genome [1174, 1175, 1185], resulting in DNA transcription 
and transgene expression [1186]. The use of AAVP for cancer cell targeting could allow for 
increased integration of AAV into the cellular genome due to increased replication activity 
of tumor cells [1187], enabling incorporation of the AAV sequence into the frequent double-
strand breaks in the DNA [1186]. The targeting capabilities and engineered tropism for cells 
specifically expressing a receptor of interest allows for gene expression with limited 
amounts of AAVP circulating after systemic administration, increasing efficacy with 
minimal toxicity [1131].  
 AAVP is an attractive vehicle for research and therapeutic investigations because it is 
relatively inexpensive to produce, but can be processed with high yields in Escherichia coli 
(E. coli) host bacteria without the addition of trans-acting factors or helper viruses. 
Moreover, there is no AAV capsid formation, eliminating any native AAV tropism to 
mammalian cells [1175]. Homing to tissue- and tumor-specific receptors is possible due to 
the inclusion of peptide ligands for display on the pIII coat protein of the phage-based 
portion of the AAVP particle [1175]. AAVP viral particles are generated as non-replicating 
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viruses that can infect mammalian cells and incorporate the TNF gene cassette into the cell 
genome for transgene expression. Systemic targeting with phage and AAVP viral particles is 
consistently effective for binding receptors displayed on normal and tumor endothelium, and 
directly targeting tumor cells expressing specific receptors has also been shown [1148, 1163, 
1188]. This capability is possible because the vascular network of tumors is generally 
disordered and leaky [306, 308-313]. This permeability allows for extravasation of 
circulating ligands into the tumor microenvironment [1132]. Our goal is to take advantage of 
this characteristic tumor pathophysiology in pancreatic NETs. As described in the previous 
section, the angiogenic processes in NETs of the pancreas expand the already well-
vascularized and fenestrated vessel network of the islets necessary for endocrine function 
and hormone distribution.  
Clinical translation of the octreotide-targeted AAVP-TNF particles could provide 
alternative options for cancer patients lacking adequate therapeutic choices. Numerous 
molecular biology, molecular-genetic imaging, and tumor-targeting studies in various 
preclinical models [1175, 1182, 1184, 1189-1191] indicate our ligand-directed AAVP-based 
system is an obvious candidate for therapeutic applications in pancreatic NETs.  
 
 
TUMOR NECROSIS FACTOR AND APOPTOSIS 
 
Tumor necrosis factor (TNF; previously cachexin, or cachectin) is a cytokine with 
variable physiologic and pathologic functions [1192-1194]. TNF binding tumor necrosis 
factor receptor type 1 (TNF-R1; also called cluster of differentiation 120 (CD120)), results 
in recruitment of a number of proteins to the receptor complex for signaling induction. The 
first proteins assembled include members of the death domain protein family. These include 
tumor necrosis factor receptor type 1-associated death domain protein (TRADD) [1195] and 
Fas-associated protein with death domain (FADD) proteins. Interaction of receptor-
interacting serine/threonine-protein kinase 1 (RIPK1) or TNF receptor-associated factor 2 
(TRAF2) with TRADD leads to activation of signal transduction pathways [1196, 1197]. 
RIPK1 is responsible for activation of inhibitor of nuclear factor kappa-B kinase (IKK) 
proteins, which, in turn, phosphorylates NF-kappa-B inhibitor alpha (NFKBIA). Because 
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NFKBIA is responsible for the sequestration of nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) in the cytoplasm, upon phosphorylation NF-κB is released from 
NFKBIA, enabling translocation of NF-κB to the nucleus for transcription activation [1198, 
1199]. TRAF2 mediates apoptosis induction along with members of the inhibitor of 
apoptosis protein (IAP) family by blocking caspase activation directly [1200, 1201]. 
Additionally, TRAF2 activates the mitogen-activated protein (MAP) kinase pathway, 
leading to c-Jun N-terminal kinase (JNK) signaling and, eventually, formation of the 
activator protein 1 (AP-1) transcription factor with roles in differentiation, proliferation, and 
apoptosis. Alternatively, FADD activation is primarily responsible for the induction of 
apoptosis. Caspase-8 recruitment upon FADD activation signals apoptosis induction 
mediated through downstream caspase processing and activation [1202-1204]. 
 The variable functions of TNF-R1 activation are mediated by internal balance and 
regulatory mechanisms. For example, inhibition of IAP family member proteins circumvents 
the anti-apoptotic pathway of TNF-R1 induced by IAP activity [1205, 1206]. Eliminating 
the IAP-mediated resistance to apoptosis results in loss of NF-κB activity and the activation 
of the FADD/caspase signaling of the TNF-R1 death domain [1207, 1208]. Preclinical trials 
with a version of AAVP-TNF targeted by the RGD peptide [36, 1144, 1209] specific for 
integrins expressed on tumor endothelium have shown significant anti-tumor responses, 
including significant tumor regression observed in spontaneous tumors in dogs [1189, 1191]. 
Inclusion of a small molecule peptide mimetic of the second mitochondria-derived activator 
of caspases (Smac; also referred to as DIABLO) protein that functions as an inhibitor of X-
chromosome linked IAP (XIAP) and cellular IAP (cIAP1 and cIAP2) proteins, increased the 
efficacy of RGD-targeted AAVP-TNF in a synergistic effect [1184]. 
 Antitumor effects of TNF require targeted or local delivery rather than systemic 
administration [1210, 1211]. However, TNF is well studied as a therapeutic agent for 
tumors. Direct administration of TNF to the tumor itself, through isolated perfusion to the 
organ or tumor specifically results in effective tumor response and limited systemic toxicity 
[1192, 1212]. Furthermore, evidence of SSTR2 activation inhibiting the anti-apoptotic 
mechanism of TNF and upregulating TNF receptor expression [1213] potentially provides 




 In addition to the benefits mentioned previously, inclusion of TNF as the gene 
delivered in our AAVP is due to two main factors. The first is that, as opposed to previous 
AAVP constructs delivering a gene suitable for imaging studies [1174, 1175, 1182, 1190], 
pancreatic NETs are currently imaged clinically with SRS and PET imaging of octreotide-
targeted radiopharmaceuticals, diminishing the necessity of incorporating a gene with 
imaging capabilities. Secondly, because this study attempts to exploit a known 
ligand/receptor pair for targeted gene delivery, previous preclinical studies with an AAVP-
TNF targeted by an integrin binding sequence provide a framework for both understanding 
experimental nuances and a somewhat comparable baseline to evaluate targeting efficiency 
[1184, 1189, 1191]. The octreotide amino acid sequence displayed in the AAVP maintains 
the cleavage sites identified for the native somatostatin peptide within and immediately 
surrounding the four critical amino acids of the beta turn region [735]. Effective homing of 
the octreotide-targeted AAVP-TNF both in vitro and in vivo requires the pIII coat protein of 
the phage virus to provide a protective conformational configuration to avoid proteases and 
maintain integrity of the targeting peptide [1214]. Evaluating a novel targeting design in 
concert with a previously untested therapeutic gene increases the number of variables 
changed and eliminates the ability to evaluate any downstream effects observed.  
 
 
THE MEN1 TRANSGENIC MOUSE MODEL 
  
 Shen et al. [54] describe the transgenic mouse model displaying the characteristics of 
MEN1 syndrome in humans that we used as our pre-clinical model for in vivo studies. This 
model evolved from a series of investigational mutations in the Men1 gene in mice in an 
attempt to recapitulate human MEN1 disease. As described in a previous section, mutations 
in the MEN1 tumor suppressor gene are inherited in an autosomal dominant pattern in 
patients with the familial MEN1 syndrome, and these patients develop tumors in two or 
more endocrine organs, often including NETs of the pancreas, through loss of MEN1 gene 
function [540, 1215]. Several iterations of mouse models of Men1 disease have been 
generated. For example, homozygous deletion of Men1 in embryonic stem cells results in 
embryonic lethality [1216, 1217]. Heterozygous mice containing one wild-type Men1 allele 
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and one mutant Men1 allele produce a variety of endocrine tumors, similar to what occurs in 
MEN1 patients. Tumors form in the pancreatic islets, thyroid, parathyroids, adrenal glands, 
and pituitary, all revealing loss of the wild-type Men1 allele [1216-1218]. Attempts to 
induce endocrine tumors of specific origin have also produced several models of Men1 
tumors in individual organs using conditional knockout models [1219]. Deletion of Men1 in 
the parathyroid glands results in hyperparathyroidism and neoplasia formation in the 
parathyroid [1220]. Models of Men1 inactivation in individual islet cell types have 
attempted to produce specific functioning tumors. Beta cell-specific deletion of Men1 
generated mice with insulinomas [1221-1223]. Inactivation of Men1 in the pancreatic alpha 
cells also resulted formation of both glucagonomas and insulinomas [1224, 1225]. 
Additional manifestations of individual Men1 tumors are continuing to be described, while 
investigators are also evaluating the molecular mechanism of Men1 activity [1226, 1227]. 
Temporal manipulation of Men1 expression reveals an increase in islet cell proliferation 
after loss of menin expression, confirming Men1 activity in cell cycle regulation [1228].  
 To study the effect of Men1 deletion from the whole pancreas, a mutant Men1 allele 
was put under control of the Pdx1 promoter to generate a conditional knockout (termed 
Pdx1-Cre;Men1 f/f) with Men1 deleted in only pancreatic tissue, recapitulating the 
characteristics of human MEN1 disease manifestation in the pancreas [54]. At the level of 
Pdx1 expression, which occurs very early in gut derivation and pancreatic organogenesis 
(described in the Background Section), the resulting loss of Men1 in these mice affects the 
entirety of the pancreas. The Pdx1-Cre;Men1 f/f mouse model represents a conditional 
knockout of Men1 tumor suppressor gene loss using the Cre-loxP system [54]. MEN1 in 
humans and Men1 in mice are highly conserved in both nucleotide and amino acid 
sequences [568-570, 1215, 1229], supporting the development of mouse models of this 
human disease. Pdx1-Cre;Men1 f/f mice are generated by crossing mice engineered to 
incorporate loxP sites at both terminal regions of the Men1 gene with mice expressing Cre 
recombinase under control of the Pdx1 promoter. As described in the Background Section, 
Pdx1 expression at such an early time point in pancreatic development provides an 
opportunity to eliminate Men1 throughout the entirety of the pancreas. The resulting mice do 
show homozygous deletion of Men1 in the entirety of the pancreas, and pancreas 
development itself is unaffected by a lack of menin during embryogenesis [54]. However, by 
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three months age, mice show increases in endocrine cell proliferation, islet vascular density, 
and structural abnormalities in islet blood vessels. These mice develop functioning tumors of 
the endocrine pancreas with no evidence of exocrine pathology or abnormality. Hyperplastic 
islets are evident at 5 to 6 months of age, and functioning insulinomas, and a corresponding 
increase in vascularization, consistently form by 10 to 12 months of age [54], following the 
progression described for tumorigenesis in hereditary NETs including MEN1 syndrome 
[269]. Additionally, the Pdx1-Cre;Men1 f/f transgenic mice show increased levels of VEGF 
expression [54], corresponding to the VEGF levels observed in other models of islet cell 
tumorigenesis as well as human tumor progression [215, 291, 298, 317, 1230]. This 
observation, combined with the high levels of vascularization observed in these mice [54], 
support the ability of the tumor microenvironment to maintain necessary levels of 
oxygenation and enable recruitment of nutrients and matrix proteins for tumor growth [296, 
317, 318, 1231]. The Men1 transgenic mice also have a significantly reduced lifespan 
compared to normal and control animals, demonstrating further similarities to MEN1 
patients [54].  
 Structural organization varies minimally in rodent and human islets, most likely in 
response to glucose requirement of variable diets. The general islet construction is similar in 
these two groups, with the five endocrine cell types present in both but with different 
distributions of the cell type frequencies and altered orientation within the islets [1232]. 
Beyond the similarities in islet architecture, utility of the Men1 mouse model for targeted 
delivery of our AAVP requires escape from the vasculature and accessibility to the tumor 
cells. The Men1 conditional knockout model shows increased vascularity and an abnormal 
vasculature with blood vessel dilation and tortuosity evident in the islet cell tumors [54]. 
SSTR expression analysis confirms high levels of SSTR2, in addition to SSTR1, SSTR3, 
and SSTR5, evident throughout the tumor of the Men1 transgenic mice, consistent with what 
is observed in human tumors [1233]. Therefore, this mouse transgenic mouse model is a 
well-defined preclinical model for studying our AAVP in the context of the complicated 
tumor microenvironment in vivo. Since this Men1 mouse model mimics human MEN1 
syndrome, and produces pancreatic NETs representative of patient tumors in both 
vascularization and SSTR2 expression, our findings in this preclinical model could be 
translatable to human disease.  
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Oligonucleotides and primers for polymerase chain reaction (PCR; Table 4) were 
purchased from Sigma-Aldrich (St. Louis, Missouri). Restriction enzymes, specifically 
AvrII (BlnI), BamHI, BglI, BglII, BssHII, EcoRI, HindIII, MluI, PstI, SfiI, and XbaI, were 
purchased from Roche Applied Science (Indianapolis, Indiana) or New England BioLabs 
(Ipswich, Massachusetts). T4 DNA Ligase was purchased from Invitrogen (Carlsbad, 
California), and the Rapid DNA Ligation Kit was purchased from Roche Applied Science. 
XL1-Blue MR supercompetent cells were purchased from Agilent Technologies (Santa 
Clara, California), DH10B and DH5α competent cells were obtained from Invitrogen, and 
K91Kan E. coli and the electrocompetent E. coli strain MC1061 are propagated and 
maintained within the laboratory. The pBluescript II KS (-) phagemid vector was purchased 
from Agilent Technologies. The pcDNA3.1 (+) plasmid containing the CMV promoter was 
acquired from Invitrogen. The filamentous phage display vectors fUSE5 [2] (GenBank 
accession: AF218364) and fMCS1 (GenBank accession: AF218733) are distributed by Dr. 
George Smith (University of Missouri; Columbia, Missouri). SOC medium was purchased 
from Invitrogen. Phosphate buffered saline (PBS; pH 7.4), Luria Bertani (LB) broth, LB-
streptomycin (100 µg/mL), LB-ampicillin (100 µg/mL), LB-kanamycin (100 µg/mL), LB-
tetracycline (40 µg/mL), and LB-kanamycin/tetracycline (100 µg/mL kanamycin and 40 
µg/mL tetracycline) plates are produced and distributed by the University of Texas M. D. 
Anderson Cancer Center Media Facility (Houston, Texas). For PCR experiments, GoTaq 
DNA polymerase and its associated reaction buffer were purchased from Promega 
(Madison, Wisconsin), deoxyribonucleotide triphosphates (dNTPs) were acquired from 
Fisher Scientific (Fair Lawn, New Jersey), and dimethyl sulphoxide (DMSO) was purchased 
from Sigma-Aldrich. Agarose was obtained from IscBioExpress (Kaysville, Utah) and E-
Gel precast agarose gels (0.8%, 2% and 4% agarose) were purchased from Invitrogen for 








































GTGAGCCGGCTGCCC  5 Insert TTCGGCCCCAGCGGC  
AGCAAGCTGATAAACCGATACAATT  6 pIII of fUSE5 CCCTCATAGTTAGCGTAACGATCT  
AGCCCATGTTGTAGCAAACC  
7  134 bp TNF 
TGAGGTACAGGCCCTCTGAT  





Table 4. PCR primers and oligonucleotides for cloning bacteriophage constructs  	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and midiprep kits were purchased from Qiagen (Valencia, California).  
 
AAVP construction and preparation – Polymerase chain reaction 
 Several steps during cloning and production of the targeted AAVP-TNF required 
amplification of a DNA fragment by PCR. Cloning pBKS/AAV required PCR amplification 
of the polyadenylation signal sequence and the 3ʹ′ ITR using primer set number 1 (Table 4). 
The PCR reaction mix utilized up to 50 nanograms (ng) of template DNA and required use 
of 7.5 percent DMSO in the reaction mix for proper amplification. In addition, the PCR mix 
contained one microliter of each primer (10 picomole per microliter (pmol/µl)), 3 microliters 
of a stock dNTP mixture at a concentration of 2.5 millimolar (mM) for each dNTP, a GoTaq 
reaction buffer volume of 20 percent, and up to 2.5 units of GoTaq polymerase. The 
optimized PCR thermocycler conditions required an initial denaturation at 95 °C for two 
minutes followed by 35 cycles of denaturation at 95 °C for 30 seconds, annealing at 60 °C 
for 30 seconds, and extension at 72 °C for one minute and then a final extension of 10 
minutes at 72 °C. The PCR product was purified using the QIAquick PCR Purification Kit. 
 Replacement of the original CMV promoter from pAAV-MCS-RR with the CMV 
promoter from the pcDNA3.1 plasmid required amplification of the CMV promoter DNA 
sequence with PCR primer set number 2 (Table 4). The reaction mix for this PCR utilized 
40 ng of template DNA in addition to one microliter of each primer from a stock 
concentration of 10 pmol/µl, two microliters of dNTPs from a stock concentration of 2.5 
mM for each dNTP, a reaction buffer volume of 10 percent, and 0.5 microliters of Taq DNA 
polymerase in a total reaction volume of 20 microliters. In addition to an initial denaturation 
at 94 °C for 2 minutes and a final extension period of 10 minutes at 72 °C, amplification of 
the PCR product required 30 cycles of denaturation at 94 °C for 30 seconds, annealing at 55 
°C for 30 seconds, and extension at 72 °C for 1 minute.  
 Preparing the TNF gene for integration into fAAV utilized PCR primer set number 4 
(Table 4). Two microliters of plasmid DNA containing the TNF DNA was added to 0.5 
microliters dNTPs, 1 microliter of each primer from a stock concentration of 10 pmol/µl, 0.3 
microliters of Taq DNA polymerase, and 4 microliters of GoTaq buffer in a 20 microliter 
reaction volume. The thermocycler settings were an initial denaturation at 95°C for 3 
minutes; 35 cycles of denaturation at 94 °C for 30 seconds, annealing at 60 °C for 60 
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seconds, and extension at 72 °C for 60 seconds; and a final 3 minutes at 72 °C. This PCR 
protocol was also used to confirm the status of the TNF gene after ligation and throughout 
the generation and expansion of the resulting AAVP particles.  
 Incorporating the octreotide amino acid sequence (FCFWKTCT) into the pIII gene 
retained from fUSE5 required primer set number 5 (Table 4) to convert the oligonucleotide 
encoding the peptide sequence to double-stranded DNA. The PCR master mix components 
and PCR settings are described in detail by Christianson et al. [1135].The oligonucleotide 
was resuspended to a stock concentration of 100 pmol/µl. Conversion of the single stranded 
template DNA to double stranded DNA required 0.5 microliters of the stock oligonucleotide 
suspension in addition to 1 microliter of each primer from a stock concentration of 10 
pmol/µl, 0.5 microliters of the dNTP mix, 0.4 microliters of DMSO, 0.3 microliters of Taq 
DNA polymerase, and a GoTaq reaction buffer volume of 20 percent in a reaction volume of 
20 microliters. The reaction conditions for the thermocycler were: 94 °C for 4 minutes; 30 
cycles of 94 °C for 30 seconds, 60 °C for 30 seconds, 72 °C for 30 seconds; and 72 °C for 5 
minutes. 
 To confirm the insert incorporation into the pIII gene of fUSE5, primer set number 6 
(Table 4) was used. The PCR master mix for this reaction required a total volume of 20 
microliters. This total included 4 microliters of GoTaq reaction buffer, 0.65 microliters of 10 
mM dNTP mix, 0.65 microliters of 25 mM magnesium chloride (MgCl2), 1 microliter of 
each primer from a stock solution of 10 pmol/µl, and 0.3 microliters of GoTaq polymerase. 
Additionally, to distinguish AAVP constructs from traditional phage particles, a small 
region (134 base pairs) of the TNF gene in fAAV-TNF and subsequent AAVP-TNF 
products were amplified simultaneously with the addition of 1 microliter of each primer (10 
pmol/µl) from primer set number 7 (Table 4) in the same PCR conditions. The thermocycler 
conditions for this PCR required 3 minutes at 94 °C; 35 cycles of 10 seconds at 94 °C, 30 
seconds at 60 °C, and 60 seconds at 72 °C; and a final 5 minutes at 72 °C. The reverse 
primer for the pIII insert into fUSE5 was used for sequencing reactions.  
 
AAVP construction and preparation – Annealing oligonucleotides 
 To expand the distance between the BglII and PstI recognition sequences in the 
multiple cloning site (MCS) of fUSE5/MCS1, a pair of oligonucleotides was designed for 
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incorporation into the XhoI and HindIII restriction enzyme sites in the MCS of 
fUSE5/MCS1. DNA oligonucleotides encompassing the region were prepared (primer set 
number 3, Table 4). These sequences contained recognition sites for XhoI, BglII, NotI, 
AvrII, PstI, and HindIII, and were designed with “sticky ends” incorporated for ligation into 
the XhoI and HindIII sites of fUSE5/MCS1 without digestion. To prepare for the ligation 
reaction, the oligonucleotides were resuspended in water to prepare a 100 pmol/µl stock 
solution for each oligonucleotide. Ten microliters from each stock solution were allowed to 
anneal in a tube suspended in water heated to 95 °C for about 5 minutes, and then cooled 
with the water to room temperature for further use. The double-stranded DNA insert was 
then ligated into the fUSE5/MCS1 plasmid DNA digested with XhoI and HindIII to form 
the fUSE5/MCS plasmid (described below). 
 
AAVP construction and preparation – Digestion, ligation, and plasmid preparation 
Cloning steps throughout the generation of the targeted AAVP-TNF required 
restriction enzyme digestion and ligation of the digested DNA. Briefly, all digestions were 
incubated in the recommended buffers and indicated temperatures according to 
manufacturer instructions. Restriction enzyme digested DNA was purified by either 
oligonucleotide and enzyme removal with the QIAquick Nucleotide Removal Kit or run in 
an agarose gel and the appropriate sized band excised and subjected to gel purification with 
the QIAquick Gel Extraction Kit. Purified digested DNA was ligated with either T4 DNA 
Ligase in its buffer or the Rapid DNA Ligation Kit with a vector to insert ratio of one to 
three. The ligation products were introduced to competent cells as the protocols described 
and the transformation mixture plated on LB plates with appropriate antibiotics. Single 
colonies were picked and suspended in a 10 percent glycerol solution for storage and further 
analysis. Colonies verified to contain the appropriate conformation were grown in small 
cultures, and the plasmid DNA recovered from overnight cultures using the QIAprep Spin 
Kits. 
To prepare the AAV components, the pAAV-MCS-RR and pBKS plasmids were 
grown in cultures of LB media and the appropriate antibiotics overnight (ampicillin; 100 
µg/mL). The following day, plasmid DNA was recovered using the Qiagen Miniprep Kit. 
Double digestions with EcoRI and PstI were incubated in the recommended buffer 
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(SuRE/Cut buffer H, Roche) at 37 °C according to manufacturer instructions. The digestion 
product for the plasmid digestions were run on an agarose gel and the appropriate bands 
excised and DNA recovered using the QIAquick Gel Extraction Kit. The DNA was ligated 
overnight with T4 DNA ligase and its appropriate ligation buffer using the protocol 
recommended by the manufacturer with a vector to insert ratio of one to three. The ligation 
reaction was used to transform XL1-Blue MR supercompetent cells according to 
manufacturer guidelines. Single colonies were recovered from the LB-ampicillin (100 
µg/mL) plates following the transformation for analysis. Small volume cultures were grown 
overnight in LB-ampicillin (100 µg/mL) and plasmid DNA recovered using the Qiagen Spin 
Miniprep Kit. Plasmid DNA was analyzed for appropriate size, and restriction mapping 
using PstI and EcoRI restriction enzymes confirmed the incorporation of the insert DNA and 
generation of pBKS/5CMV. This intermediate vector was then used to generate 
pBKS/AAV. 
 The insert containing the polyadenylation signal and 3ʹ′ ITR (described in the section 
on PCR) and pBKS/5CMV vector DNA were digested with EcoRI and HindIII in the 
appropriate buffer (NEBuffer 2, New England Biolabs) at 37 °C per manufacturer 
instruction. The digestion products were gel purified and ligated as described above. The 
ligation reaction was used to transform XL1-Blue MR supercompetent cells per 
manufacturer instructions. Single colonies were picked and evaluated for incorporation and 
the correct configuration. Small cultures were grown overnight and plasmid DNA recovered 
with the Qiagen Spin Miniprep Kit. Incorporation of the insert was confirmed with PCR 
using primer set number 1 (Table 4) and DNA sequencing, and restriction enzyme mapping 
confirmed the size and orientation of the resulting pBKS/AAV* plasmid.  
 Replacement of the CMV promoter required amplification of the CMV promoter 
region from the pcDNA3.1 vector using primer set number 2 (described above). Purified 
insert DNA was initially incubated with the AvrII restriction enzyme in NEBuffer 2 (New 
England Biolabs) for 1 hour at 37 °C, then the BssHII enzyme was added and the digestion 
was transferred to 50 °C for an additional hour to complete the digestion. Vector DNA was 
digested in a double digest with both AvrII and MluI enzymes in the appropriate buffer 
(SuRE/Cut buffer H, Roche) at 37 °C for 1 hour. The digestion products were run on an 
agarose gel, the DNA extracted, and ligated using T4 DNA Ligase, per manufacturer 
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instructions. Ligated DNA was used to transform XL1-Blue MR supercompetent cells 
according to the protocol provided by the manufacturer. Subsequent colonies were used to 
grow small cultures, and the plasmid DNA recovered. Restriction enzyme mapping with PstI 
and EcoRI enzymes was used to confirm the incorporation and generation of pBKS/AAV.  
Preparation of the phage component required the reorganization of the fUSE5 and 
fMCS1 filamentous phage genomes. Plasmid DNA from both phage vectors was used for a 
double digestion with XbaI and BamHI restriction enzymes and the appropriate buffer 
(SuRE/Cut buffer A, Roche) at 37 °C. The digestion products were run on an agarose gel, 
and the appropriate sized bands excised with a blade for DNA recovery. T4 DNA ligase was 
used to ligate the digested DNA, according to manufacturer guidelines, to prepare 
fUSE5/MCS1. The ligated DNA was used to transform competent cells, and stock E. coli 
was prepared for further use. To replace the MCS, a large culture of fUSE5/MCS1 was 
grown overnight, and plasmid DNA was recovered using the Qiagen Plasmid Midiprep Kit. 
About 500 nanograms (ng) of plasmid DNA was double digested with XhoI and HindIII 
restriction enzymes and the appropriate digestion buffer (SuRE/Cut buffer B, Roche) 
according to manufacturer instructions at 37 °C. Digested DNA was run in an agarose gel 
and the appropriately sized band excised and gel purified using the Qiagen QIAquick Gel 
Extraction Kit. A ligation reaction was performed using purified digested fUSE5/MCS1 
DNA and the annealed multiple cloning site insert DNA described above (in the Annealing 
oligonucleotides section) using T4 DNA ligase and its recommended buffer according to 
manufacturer instructions. Individual colonies were picked and evaluated and grown in 
small cultures overnight. Plasmid DNA was recovered with the Qiagen Spin Miniprep Kit 
and evaluated for incorporation of the insert sequence using restriction enzyme mapping to 
confirm formation of fUSE5/MCS. 
 Combining the AAV and phage components to generate the fAAV construct required 
double digestion of both plasmids with enzymes that form compatible ends upon digestion. 
Plasmid DNA from fUSE5/MCS was digested with BglII and PstI in the appropriate buffer 
(SuRe/Cut buffer H, Roche), while DNA from pBKS/AAV was digested with BamHI and 
SbfI in a buffer suitable for both restriction enzymes (NEBuffer 4, New England Biolabs), 
for 2 hours at 37 °C. The digestion products were run on an agarose gel, the appropriate 
bands excised, and digested DNA purified. The two digestion products were ligated with T4 
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DNA ligase, per manufacturer instructions, and the ligated DNA used to transform XL1-
Blue MR supercompetent cells according to the protocol provided. The resulting colonies 
were evaluated for integration using restriction enzyme mapping to identify individual 
clones with the correct conformation of the fAAV plasmid.  
 The PCR product encompassing the TNF DNA sequence and containing XbaI and 
BamHI restriction enzyme recognition sequences was purified using the PCR Purification 
kit per manufacturer instructions. Four microliters of the recovered DNA was digested with 
XbaI and BamHI restriction enzymes in the recommended buffer (SuRe/Cut buffer A, 
Roche) overnight at 37 °C. Simultaneously, fAAV plasmid DNA was digested with BlnI 
and BglII restriction enzymes and NEBuffer 3 (New England Biolabs) overnight at 37 °C. 
The following day, the digestion products were cleaned with the Nucleotide Removal Kit, 
and the digested DNA ligated using the Rapid DNA Ligation Kit according to manufacturer 
instructions. The ligated DNA was heat-shocked into XL1 Blue MR supercompetent cells as 
described in the manufacturer protocol. The small culture was plated on LB-tetracycline (40 
µg/mL) plates and incubated overnight at 37 °C. Individual colonies were picked with 
toothpicks and suspended in a 10 percent glycerol solution for validation by PCR using the 
primers for the TNF DNA (primer set number 4; Table 4). Small cultures were grown 
overnight, and the fAAV/TNF plasmid DNA was recovered the next day using the Qiagen 
Miniprep Kit.  
Integration of the targeting sequence into the pIII gene of fAAV/TNF followed the 
traditional laboratory protocol for generation of phage libraries in fUSE5 [1135]. After 
amplification with PCR, the insert DNA was digested with the BglI enzyme as described by 
the manufacturer. The fAAV-TNF vector DNA was digested per manufacturer instructions 
with the SfiI restriction enzyme to remove the 14 base pair stuffer DNA in the pIII gene-
encoding region. The digestion products were purified using the QIAquick Nucleotide 
Removal Kit to remove the digestion contaminants. The purified digestion products for the 
octreotide insert and fAAV-TNF vector were then ligated using the Rapid DNA Ligation Kit 
as described by the manufacturer. A vector to insert ratio of one to three was effective for 
successful ligation. The ligation product was introduced into XL1-Blue MR supercompetent 
cells using the transformation protocol provided by the manufacturer. One hundred 
microliters of the resultant transformation mixture was plated on LB-tetracycline plates and 
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incubated overnight at 37 °C. Individual colonies were recovered from the plates and 
suspended in a 10 percent glycerol stock. These colonies were subjected to PCR 
amplification of the pIII region using the primer set number 6 (Table 4) and sequenced to 
determine correct incorporation of the insert. Colonies with the correct conformation for 
Oct-AAVP-TNF were grown in small cultures overnight in LB-tetracycline (20 µg/mL), and 
plasmid DNA was then recovered from the cultures using the QIAprep Spin Miniprep Kit.  
 
AAVP construction and preparation – Particle amplification 
One microliter of the miniprep DNA for Oct-AAVP-TNF was electroporated into the 
electrocompetent E. coli strain MC1061. The transformed bacteria was added to one 
milliliter of SOC medium, shaken for one hour at about 225 revolutions per minute (RPM) 
at 37 °C, plated on LB-tetracycline plates, and incubated overnight at 37 °C. Single colonies 
were picked the following day and transferred to a 10 percent glycerol solution for storage. 
To produce the original stock AAVP particles, a small volume of the colony suspension was 
amplified for phage particle production using the protocol described by Hajitou et al. [1174]. 
Briefly, two microliters of the colony suspension was transferred to 500 milliliters of LB-
tetracycline (20 µg/mL) and grown overnight at 37 °C. After centrifugation to remove the 
bacterial debris, AAVP particles were purified from the resultant culture supernatant by 
precipitation with a polyethylene glycol (PEG) and sodium chloride (NaCl) solution, 
resuspended in PBS (pH 7.4), and repeatedly centrifuged to remove any remaining debris 
[1135].  
A small volume (from two to five microliters) of the purified supernatant containing 
AAVP particles in suspension was then used to infect 500 microliters of K91Kan E. coli for 
amplification and phage particle production at a higher titer for experimental use. The 
bacterial infection was transferred to 500 milliliters of LB-kanamycin/tetracycline (100 
µg/mL kanamycin and 20 µg/mL tetracycline), grown overnight, and phage particles 
recovered the following day [3, 1135, 1174]. Sequencing the insert sequence in fUSE5 using 
primer set number 6 (Table 4) throughout production and subsequent amplification of the 
phage particles was critical for ensuring the integrity of the phage preparation. Insertless 
control AAVP constructs derived from the empty fd-tet vector were amplified in parallel 
with the octreotide-targeted AAVP-TNF vector for experimental use. 
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AAVP construction and preparation – Titration 
The Oct-AAVP-TNF suspension was titrated in parallel with insertless control 
AAVP by bacterial infection with K91Kan E. coli to determine the number of transducing 
units (TU). To do this, a serial dilution of the AAVP suspension was prepared, and the 
dilutions (107 to 109) were infected with K91Kan E. coli for 30 minutes at room 
temperature. The infection was plated on LB-kanamycin/tetracycline (100 µg/mL 
kanamycin and 40 µg/mL tetracycline) plates and incubated overnight at 37 °C. Colonies 
were counted the following day and titers determined [1234]. Titers were analyzed over time 
and prior to individual experiments as necessary to ensure correct input and maintain 
experimental integrity. 
 
Generation of bacteriophage constructs 
 Simultaneous to generation of the AAVP-TNF constructs described above, 
octreotide-targeted and insertless (fd-tet) [1235] control phage were also generated using the 
traditional laboratory protocol [1135], modified for incorporation of a known targeting 
sequence to provide an estimate of binding efficacy. The first step in generating the phage 
constructs was to convert the single stranded DNA oligonucleotide to double stranded DNA 
using PCR. The PCR master mix components and thermocycler settings are described above 
and detailed by Christianson et al. [1135]. Generation of the octreotide-targeted phage 
required conversion of the single-stranded oligonucleotide encoding the FCFWKTCT insert 
(Table 4) to double-stranded DNA using primer set number 5 (Table 4).  
 After amplification with PCR, the octreotide insert DNA was digested with the BglI 
enzyme as described by the manufacturer. The fUSE5 vector was digested per manufacturer 
instructions with the SfiI restriction enzyme to remove the 14 base pair stuffer DNA in the 
pIII gene-encoding region. The digestion products were purified using the QIAquick 
Nucleotide Removal Kit to remove the digestion contaminants and extraneous DNA. The 
purified digestion products for the inserts and fUSE5 vector were then ligated using the 
Rapid DNA Ligation Kit as described by the manufacturer in a vector to insert ratio of one 
to three.  
 The ligation product was introduced into XL1-Blue MR supercompetent cells using 
the transformation protocol provided by the manufacturer. One hundred microliters of the 
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resultant transformation mixture was plated on LB-tetracycline plates and incubated 
overnight at 37 °C for colony growth. Individual colonies were picked from the plates using 
toothpicks and suspended in a 10 percent glycerol stock. These colonies were subjected to 
PCR amplification of the pIII region using primer set number 6 (Table 4) and sequenced to 
determine correct incorporation of the insert. Colonies with the correct conformation were 
grown in small cultures overnight in LB-tetracycline (20 µg/mL), and plasmid DNA was 
recovered from the cultures using the QIAprep Spin Miniprep Kit. One microliter of the 
recovered miniprep DNA was electroporated into the electrocompetent E. coli strain 
MC1061. The transformed bacteria was added to one milliliter of SOC medium, shaken at 
37 °C, plated on LB-tetracycline (40 µg/mL) plates, and incubated overnight at 37 °C. 
Single colonies were picked the following day and transferred to a 10 percent glycerol 
solution for long-term storage at -20 °C.  
To produce the original stock phage particles, an individual colony was amplified for 
phage particle production using the protocol described by Hajitou et al. [1174]. Briefly, two 
microliters of the colony suspension is transferred to 500 milliliters of LB-tetracycline (20 
µg/mL) and grown overnight at 37 °C. Phage particles were then purified from the resultant 
culture after centrifugation to remove the bacteria and precipitation with a PEG/NaCl 
solution [1135]. A small volume (from two to five microliters) of the stock phage was then 
used to infect 500 microliters of K91Kan E. coli for amplification and phage particle 
production at a higher titer for experimental use. The bacterial infection was transferred to 
500 milliliters of LB-kanamycin/tetracycline (100 µg/mL kanamycin and 20 µg/mL 
tetracycline), grown overnight, and phage particles recovered the following day [1135, 
1174]. Sequencing the insert sequence in fUSE5 using primer set number 6 (Table 4) 
throughout production and subsequent amplification of the phage particles ensured the 
integrity of the phage preparation over time.  
The octreotide phage was titrated in parallel with insertless control (fd-tet) phage by 
bacterial infection with K91Kan E. coli to determine the number of transducing units. To do 
this, serial dilution of the phage suspensions were prepared, and the dilutions infected with 
K91Kan E. coli for 30 minutes at room temperature. The infection was then plated on LB-
kanamycin/tetracycline (100 µg/mL kanamycin and 40 µg/mL tetracycline) plates and 
incubated overnight at 37 °C. Colonies were counted the following day and titers 
	  	  
49	  
determined. Titers were analyzed over time and prior to individual experiments as necessary 
to ensure correct input and ensure experimental integrity. 
 
 
RECEPTOR BINDING AND INHIBITION ASSAYS 
 
Binding assay 
Octreotide-targeted or insertless control phage and AAVP-TNF constructs were 
evaluated for the ability to bind SSTRs (SSTR1, SSTR2, SSTR3, and SSTR5), GST, and 
BSA immobilized on microtiter wells, as described previously [19, 21]. SSTR1 (catalog 
number H00006751-P01), SSTR2 (catalog number H00006752-P01), SSTR3 (catalog 
number H00006753-P01), and SSTR5 (catalog number H00006755-P01) recombinant 
proteins and GST epitope tag protein (catalog number P0001) were purchased from Novus 
Biologicals (Littleton, Colorado). Fifty nanograms of each SSTR or control protein was used 
to coat duplicate wells for each phage or AAVP. After allowing the proteins to adhere 
overnight, the wells are washed once with PBS (pH 7.4) and then a 3 percent bovine serum 
albumin (BSA; Sigma-Aldrich) solution in PBS was used to block non-specific binding 
during a 1 hour incubation at room temperature. The blocking buffer was removed and 109 
transducing units (TU) of either targeted or control phage or AAVP was added to each well 
and left at room temperature for about 2 hours. Unbound particles were then removed in 15 
to 20 washes with PBS, while bound AAVP was recovered by bacterial infection for one 
hour with the addition of 100 microliters of K91Kan E. coli (OD600 = 0.180 - 0.200). The 
infection was transferred to 10 milliliters LB-kanamycin/tetracycline (100 µg/mL 
kanamycin and 20 µg/mL tetracycline) for 30 minutes and then 10 and 100 microliters were 
plated in duplicate on LB-kanamycin/tetracycline plates (100 µg/mL kanamycin and 40 
µg/mL tetracycline). The plates were incubated at 37 °C overnight, and the colonies counted 
the following day.  
 
Inhibition assay 
Competitive inhibition with synthetic octreotide peptide was also evaluated for a 
dose-dependent effect, as described previously [19, 21]. Octreotide-targeted or control (fd-
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tet) phage were evaluated for the ability to bind SSTR2, GST, and BSA immobilized on a 
96-well plate after the addition of synthetic peptide. Briefly, after allowing the protein to 
adhere to microtiter wells overnight, the wells are washed once with PBS and blocked with 
3 percent BSA as described for the binding assay above. Increasing concentrations of 
synthetic octreotide acetate peptide (catalog number H-5972; Bachem) were added to the 
adhered SSTR2 and control proteins for 30 minutes, followed by incubation with 109 TU of 





The NCI-H727 (ATCC number CRL-5815) neuroendocrine tumor cell line was 
purchased from the American Type Culture Collection (ATCC; Manassas, Virginia). NCI-
H727 cells were grown in RPMI 1640 medium containing L-glutamine supplemented with 
10 percent fetal bovine serum (FBS), penicillin (100 units/mL), and streptomycin (100 
µg/mL) at 37 °C in 5 percent carbon dioxide (CO2). Prior to use, cells were detached with 
5mM ethylenediaminetetraacetic acid (EDTA) in PBS and counted using the Bio-Rad TC10 
Automated Cell Counter.  
 
 
FLOW CYTOMETRY ANALYSIS OF SSTR2 EXPRESSION 
 
 Primary monoclonal antibodies against human SSTR2 (catalog number MAB4224) 
or mouse IgG isotype control (catalog number MAB0031) were purchased from R&D 
Systems (Minneapolis, MN). Fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse 
IgG secondary antibody (catalog number 115-095-146) was acquired from Jackson 
ImmunoResearch Laboratories (West Grove, Pennsylvania). NCI-H727 cells (3 x 105 cells 
per tube) were incubated with a primary antibody against human SSTR2 or isotype control 
at a concentration of 25 µg/mL for one hour on ice in the dark. Cells were washed three 
times, using centrifugation at 350 xg to pellet the cells followed by resuspension in ice cold 
PBS. The FITC-conjugated goat anti-mouse secondary antibody was diluted in PBS (1:150), 
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and the cell pellet after the third wash was resuspended in 150 µL of the secondary antibody 
solution for 20 minutes on ice in the dark. The cells were washed three times, as before, and 
resuspended in 150 µL ice cold PBS. Flow cytometry analysis was performed immediately 
with the BD FACSCanto II flow cytometer. Analysis of FITC expression from the cells was 
performed with FlowJo (version 8.8.7) software. 
 
 
BINDING AND RAPID ANALYSIS OF SELECTIVE 
INTERACTIVE LIGANDS (BRASIL) CELL BINDING ASSAY 
 
Bovine serum albumin (BSA), dibutyl phthalate, and cyclohexane were purchased 
from Sigma-Aldrich. The protocol for BRASIL cell binding analysis has been described [21, 
1135]. Following detachment with 5 mM EDTA, NCI-H727 cell suspensions were spun 
down at 500 xg (relative centrifugal force, RCF) for 5 minutes to pellet the cells and then 
resuspended in 1 percent bovine serum albumin in minimum essential medium (BSA/MEM) 
at 106 cells per milliliter and kept on ice. Aliquots of the cell suspension were incubated with 
10 µL of a 1 mM stock solution of synthetic somatostatin-14 peptide (catalog number H-
1490; Bachem) on ice with occasional flicking to disperse the cell/peptide mixture. After 30 
minutes, 109 TU targeted or insertless control AAVP-TNF was added to the tubes and the 
suspension was incubated on ice for two hours. Following this incubation, the unbound 
AAVP was separated from the cells through a differential centrifugation technique. First, 
200 µL of a 9:1 (v:v) mixture of dibutyl phthalate:cyclohexane (termed BRASIL oil) was 
added to microcentrifuge tubes with attached caps and a volume of 0.4 mL (VWR Scientific 
Products; West Chester, Pennsylvania). Then, 100 µL of the cell suspension was added to 
each tube, and the tubes were spun at 10,000 xg for 10 minutes. The cell pellets were 
carefully removed using microcentrifuge cutters (Bel-Art Products; Pequannock, New 
Jersey) over a 50 mL tube to allow the tips containing the cell pellets to fall into the large 
tube, and extraneous oil was removed from the tip by pipetting. To recover the bound 
AAVP, 200 µL K91kan E. coli (OD600 = 0.180 - 0.200) was added to the tip and pipetted up 
and down to mix thoroughly. After an incubation of 1 hour, 20 mL LB-kan/tet (100 µg/mL 
kanamycin and 20 µg/mL tetracycline) was added to each 50 mL tube. Ten microliters and 
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100 µL of the LB suspension were plated in triplicate on LB-kan/tet plates (100 µg/mL 
kanamycin and 40 µg/mL tetracycline) and incubated overnight at 37 °C. The following day, 
colonies were counted to determine binding efficiency in the varying conditions. 
 
 
AAVP INTERNALIZATION ASSAY 
 
Rabbit anti-fd bacteriophage antibody (catalog number B7786) was purchased from 
Sigma-Aldrich. Normal rabbit immunoglobulin G (IgG; catalog number 011-000-003), Cy3-
conjugated goat anti-rabbit IgG secondary antibody (catalog number 111-165-045), and 
normal goat serum (catalog number 005-000-121) were purchased from Jackson 
ImmunoResearch Laboratories. To evaluate AAVP internalization, 5 x 104 cells were seeded 
per well in Nunc Lab-Tek II 8-well glass chamber slides (catalog number 154941; Fisher 
Scientific) and allowed to attach overnight at 37 °C in 5 percent CO2. The following day, 30 
percent FBS supplemented minimal essential medium (FBS/MEM) was used to block non-
specific binding for 1 hour at 37 °C. The cells were then incubated with 109 TU octreotide or 
control AAVP-TNF in 2 percent FBS/MEM for 2 or 24 hours. Negative control wells were 
incubated with 2 percent FBS/MEM alone. At each indicated time point, the AAVP 
suspension or medium was aspirated from each well, and the cells were washed five times 
with 10 percent BSA in PBS (BSA/PBS). The cells were then washed three times with 
glycine buffer (20 mM glycine, 150 mM NaCl; pH 2.3). This washing step required 3 
minutes of slight shaking for each wash to remove bound phage particles from the cell 
surface. The cells were then washed three times with PBS and fixed with a 15 minute 
incubation in freshly prepared 4 percent paraformaldehyde in PBS. Following fixation, the 
cells were again washed three times with PBS, and one set of wells for each experimental 
condition was permeabilized with 0.2 percent Triton X-100 (catalog number T9284; Sigma-
Aldrich) for five minutes. The cells were then washed five times with PBS and blocked with 
5 percent normal goat serum in 1 percent BSA/PBS for 30 minutes. Immediately following 
the blocking, anti-bacteriophage antibody (1:500 dilution in 1 percent BSA/PBS) was added. 
Non-immune anti-rabbit IgG (1:1000 dilution in 1 percent BSA/PBS) was prepared for one 
set of wells as a negative control. After incubation for 1 hour, the wells were washed five 
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times with 1 percent BSA/PBS, and the secondary antibody (Cy3-conjugated goat anti-
rabbit IgG in a 1:300 dilution in 1 percent BSA/PBS) was added to each well and the slides 
kept in the dark for 30 minutes. Following this incubation, the wells were washed five times 
with 1 percent BSA/PBS and fixed with fresh paraformaldehyde (4 percent in PBS) for 15 
minutes. The cells were washed twice more with PBS and the slides mounted. Vectashield 
mounting medium with DAPI (4ʹ′, 6-diamidino-2-phenylindole; Vector Laboratories; 
Burlingame, California) was added to each well and a cover slip was secured in place with 
Cytoseal mounting medium to maintain integrity. The slides were allowed to set in the dark 
overnight at 4 °C prior to visualization. AAVP internalization into NCI-H727 cells was 
visualized with a fluorescence microscope.  
 
 
TRANSGENE EXPRESSION IN VITRO 
 
 TNF gene expression analyses were carried out in vitro as described previously 
[1174, 1191]. Cells were seeded at a concentration of 5 x 104 cells per well in a 24-well 
plate in 0.5 mL complete medium and incubated overnight at 37 °C in 5 percent CO2. Three 
wells were prepared for each experimental condition: targeted AAVP, insertless control 
AAVP, and medium alone without AAVP. When the cells reached about 50 percent 
confluency, 5 x 1010 transducing units of octreotide-targeted or insertless control AAVP-
TNF was added in 200 µL RPMI 1640 medium alone without FBS to ensure transduction 
efficiency [1174]. The plate was tilted every 15 minutes for 4 hours, after which 0.3 mL of 
complete medium was added to the wells for a total of 0.5 mL. The cells were incubated at 
37 °C in 5 percent CO2 for 10 days. Every 2 days, the medium was refreshed for the cells 
and the culture supernatant collected. The collected supernatant was immediately transferred 
to -20 °C for storage until the levels of secreted TNF in the liquid could be measured to 
determine gene expression levels in the transduced cells.  
 Culture supernatant was evaluated using an enzyme-linked immunosorbent assay 
(ELISA) kit for human TNF [1184, 1191]. This ELISA kit (catalog number KHC3012, 
Invitrogen) uses anti-human TNF monoclonal antibody coated wells to evaluate samples in a 
sandwich ELISA compared to standards. The manufacturer instructions and assay protocol 
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were followed. To determine the sample values, first a scatter plot was prepared in a 
Microsoft Excel spreadsheet plotting the values of the logarithm to base 10 (log) of the 
standard concentration values against the log of the average optical densities (OD) for each 
standard value after subtraction of the value for the blank well. A linear trendline was 
established in the graph and the equation of the line determined from the software. To 
evaluate the samples, first, the value of the blank well was subtracted from all OD values for 
the plate. Then, the log of each of the values was incorporated into the linear equation and 
the value of  “x” was found for each value, and the inverse log was then calculated for each 
sample to determine the value of TNF in each sample.  
 
   
ANIMAL CARE 
 
Pdx1-Cre;Men1 f/f transgenic mice were maintained in accordance with governing 
standards and all experiments were conducted according to protocols approved for 
institutional compliance.  
 
 
MEASUREMENT OF SERUM INSULIN LEVELS 
 
 Serum insulin was measured as described previously [54, 1233]. Following an 18 
hour fast, blood was collected via retro-orbital bleeding using 0.5 mol/L EDTA as an 
anticoagulant for analysis with the Ultrasensitive Mouse Insulin ELISA kit (Mercodia, Inc.;	  
Uppsala, Sweden), according to the manufacturer’s instructions.   
 
 
AAVP HOMING IN MEN1 TRANSGENIC MICE 
 
Three 12-month-old Men1 mice (Pdx1-Cre;Men1 f/f) with known tumors (based on 
measurement of serum insulin levels as described above) were used per experiment. Control 
animals were analyzed in parallel. Octreotide-targeted AAVP-TNF (1011 TU) was 
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administered intravenously into the tail vein of Men1 or control mice under anesthesia. After 
the AAVP was allowed to circulate for 4 days, the mice were sacrificed and organs and 
tissues of interest were recovered for analyses. Resected pancreas, including any tumors, and 
normal tissues (brain, heart, lung, spleen, liver, skeletal muscle, and kidney) were flash-
frozen and stored at -80°C. Small sections of each tissue sample were formalin-fixed and 
paraffin-embedded for immunofluorescent analysis. Peripheral blood was also collected 
from all animals at days 0 and 4. To evaluate AAVP homing, the paraffin sections (5 µM) 
were analyzed by dual immunofluorescence. The sections were incubated with 5 percent 
normal goat serum in 2.5 percent BSA/PBS for 1 hour at room temperature to block non-
specific binding, followed by incubation with rabbit anti-phage (1:1000 dilution; Sigma-
Aldrich) and guinea pig anti-swine insulin (1:500 dilution; DAKO) primary antibodies 
overnight. After washing, the slides were incubated with goat anti-rabbit Alexa Fluor 488 
and goat anti-guinea pig Alexa Fluor 647 (both 1:200 dilutions; Invitrogen) for 45 minutes 
in the dark. The slides were then mounted in Vectashield mounting medium with DAPI 
(Vector Laboratories) and allowed to set. Images were taken using a fluorescence 
microscope with an attached camera [1184, 1189, 1191, 1233]. 
 
 
TNF EXPRESSION IN VIVO  
 
Gene expression assay – ELISA 
TNF expression in vivo was evaluated by ELISA, as described above and in previous 
reports [1184, 1191]. Total cell lysates from frozen pancreas including any tumors, control 
tissues (brain, heart, lung, spleen, skeletal muscle, liver, and kidney), and peripheral blood 
recovered before and after treatment were prepared in lysis buffer (50 mM Tris-HCl, pH 7.4; 
140 mM NaCl; 0.1% sodium dodecyl sulfate; 1% NP-40; and 0.5% sodium deoxycholate) 
containing a protease inhibitor cocktail (Roche). The lysates were cleared by centrifugation 
(13,000 rpm for 10 minutes), and protein was quantified with a protein assay reagent 
(BioRad; Hercules, California). 100 micrograms of total protein was assayed for the 
presence of human TNF using ELISA (catalog number KHC3012, Invitrogen) and 




Gene expression assay – Real-time RT-PCR 
Human TNF messenger RNA (mRNA) was measured by real-time reverse 
transcription (RT) PCR with primer and probe sequences specific for the human TNF 
sequence present in octreotide-targeted and insertless control AAVP-TNF (sense primer: 5ʹ′ - 
TTCAGCTCTGCATCGTTTTG - 3ʹ′, antisense primer: 5ʹ′ - CTCAGCTTGAGGGTTTGC 
TACA - 3ʹ′, and probe 5ʹ′ - FAM - TTCTCTTGGCGTCAGATCATCTTCTCGAAC - 
TAMARA - 3ʹ′) [1184, 1189]. Total RNA was extracted from the frozen tissues (pancreas 
with any tumor, brain, heart, lung, spleen, liver, muscle, and kidney) as well as tissues 
recovered from laser capture microdissection (described below) with Trizon (Invitrogen) 
and the RNeasy Total RNA Kit (Qiagen). cDNA was first generated from RNA, and 
quantitative RT-PCR was performed with a Gene Amp 7500 Sequence Detector (Applied 
Biosystems/Invitrogen). Measurements of fluorescent signal intensity after standardization 
with an 18S ribosomal RNA (rRNA) internal control allowed quantification.  
 
 
LASER CAPTURE MICRODISSECTION 
 
 Three 5 µM thick paraffin sections were used for laser capture microdissection 
(LCM) with the Leica LCM Microsystem (Buffalo Grove, Illinois). Excised tissue was 





Statistical analyses were performed using the functions of the Microsoft Excel 
software. Error bars indicate the standard deviation of the mean. Significance was 
determined between indicated groups using an unpaired, two-tailed Student’s t test. p values 
less than 0.05 were considered statistically significant and are indicated in the charts with 






 To evaluate the hypothesis that octreotide displayed in the AAVP vector could 
recapitulate the binding activity of the native peptide and allow targeted gene delivery 
specifically to NET cells expressing SSTR2 required construction of an octreotide-targeted 
AAVP with TNF as a therapeutic reporter gene followed by evaluation of activity in vitro 




CLONING STRATEGY FOR AAVP 
 
Generation of the octreotide-targeted AAVP gene delivery vector containing TNF 
required multiple steps and intermediate vectors. Both AAV and phage components were 
engineered to ensure correct orientation during construction and proper function of the 
resultant viral particles [1174, 1175]. Initially, the AAV components were prepared. The 5ʹ′ 
and 3ʹ′ inverted terminal repeats (ITRs), the cytomegalovirus (CMV) promoter gene cassette, 
and the polyadenylation (poly(A)) signal of AAV were recovered from a derivative of the 
pAAV-MCS plasmid, called pAAV-MCS-RR. The pAAV-MCS-RR plasmid had a new 
multiple cloning site (MCS) inserted between the PstI and EcoRI restriction enzyme sites of 
a pAAV-MCS commercial plasmid that provided additional cloning opportunities for later 
modifications.  
To prepare the AAV-based vector controlled by CMV promoter (pBKS/AAV), the 
AAV components from pAAV-MCS-RR were transferred to the pBluescript cloning vector 
(pBKS: pBluescript II KS (-)) in a two-step cloning process. Generating the pBKS/AAV 
plasmid containing both 5ʹ′ and 3ʹ′ ITRs for AAV genome integration and the strong and 
ubiquitous CMV promoter, first required production of the intermediate pBKS/5CMV 
plasmid (4.3 kilobase (kb)). To do this, the pAAV-MCS-RR plasmid was digested with PstI 
and EcoRI restriction enzymes, and the resulting 1.3 kb DNA fragment carrying the 5ʹ′ ITR 
and the CMV promoter was subcloned into the PstI and EcoRI sites of pBKS (Figure 1).  
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Next, the fragment from pAAV-MCS-RR containing the poly(A) tail and the 3′ ITR 
(0.7 kb) was amplified using primer set number 1 (Table 4). These primers maintain the PstI 
and PvuII sites of the 3ʹ′ end for further use while incorporating a HindIII cut site. The newly 
created HindIII site and the EcoRI site maintained from the 5ʹ′ end were used to clone the 
pAAV-MCS-RR 
(4.7 kb) 
5’ 3’ CMV pA 
PstI 
PvuII MluI EcoRI SbfI PvuII 
1.3 kb pAAV-MCS-RR 
(4.7 kb) 
5’ 3’ CMV pA 
PstI 















5’ 3’ CMV pA 









5’ 3’ CMV pA 











Figure 1. Cloning strategy for AAV components. The AAV components from pAAV-
MCS-RR were transferred to the pBluescript cloning vector (pBKS) in two steps to create 
the pBKS/AAV* vector. This process allowed for the incorporation of a new MCS to 
increase the number of potential restriction enzyme sites and vary their orientations for 
further modification. Additionally, the CMV promoter from pAAV-MCS-RR was replaced 
with another CMV promoter from the pcDNA3.1 plasmid to limit the size of the AAV 
region while maintaining transduction capabilities.	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fragment into pBKS/5CMV. The resulting plasmid, pBKS/AAV* (5.0 kb), contains the 5ʹ′ 
ITR and 3ʹ′ ITR at both terminal regions of the CMV promoter gene cassette as well as the 
polyadenylation signal (Figure 1). Additionally, to ensure maximal gene expression levels 
were achieved, the original CMV promoter from pAAV-MCS-RR was replaced with 
another CMV promoter from the pcDNA3.1 (+) plasmid. The CMV promoter DNA was 
recovered from the plasmid using PCR primer set number 2 (Table 4). These primers were 
designed to incorporate restriction enzyme recognition sequences for BssHII and AvrII 
enzymes on the 5′ and 3′ terminal regions, respectively, for cloning into MluI and AvrII sites 
of the original pBKS/AAV* DNA (Figure 1). The pcDNA3.1 CMV promoter includes the 
complete enhancer region for CMV activity but does not contain the intron within the 
promoter, decreasing the size of the promoter region, while ensuring the transduction 
capabilities of pBKS/AAV. 
The fUSE5 phage display vector has two SfiI restriction enzyme recognition 
sequences in the pIII gene for displaying peptides on the viral coat protein. However, fUSE5 
does not contain an easily accessible sequence for integration of the large AAV sequence 
necessary to generate AAVP. However, another phage vector of the same lineage, fMCS1, 
does possess a MCS region in an untranslated region of the phage genome for cloning 
applications. The cloning strategy for the phage component of the AAVP vector, therefore, 
entailed combining the necessary elements of these two filamentous phage vectors to create 
a new phage display vector containing both the SfiI sites in the pIII coat protein from the 
fUSE5 vector and the multiple cloning site from the fMCS1 vector for cloning. The 
filamentous phage display vector fUSE5 was cut with BamHI and XbaI, and the resulting 
3.9 kb DNA fragment was subcloned into the BamHI and XbaI sites of the fd-tet-based 
filamentous phage display vector, fMCS1, possible because of their shared lineage. The 
resulting phage genome containing the elements from both fUSE5 and fMCS1, designated 
fUSE5/MCS1 (8.9 kb), is shown in Figure 2. Additionally, although the MCS sequence 
from fMCS1 contains both the BglII and PstI restriction enzyme cut sites necessary for the 
incorporation of the AAV components into the phage genome, the recognition sites for these 
enzymes overlap in the original MCS. To overcome this potentially limiting factor, a stuffer 
DNA fragment was engineered for incorporation into the XhoI and HindIII sites of the MCS 
to extend the distance between the BglII and PstI recognition sites to ensure complete 
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digestion and increase ligation efficiency. Forward and reverse DNA primers encompassing 
the region were prepared for incorporation into the original multiple cloning site (Figure 2).  
To clone the AAVP vector (fAAV), the AAV components from pBKS/AAV and the 
phage display vector fUSE5/MCS were combined. The fAAV phage display vector was 
generated by cloning the 1.8 kb fragment resulting from pBKS/AAV digestion with BamHI 
and SbfI into the BglII and PstI sites of the fUSE5/MCS vector. The resulting AAVP vector 
(fAAV; 10.7 kb) contains the 5ʹ′ and 3ʹ′ ITRs, CMV promoter, and polyadenylation signal of 




























Substitution of MCS1 with new MCS 
MCS 
XhoI      BglII      NotI      AvrII     PstI     HindIII  
MCS of fMCS1 
XhoI       BglII      PstI       PvuII     KpnI    HindIII 
5,673 5,695 
Figure 2. Cloning strategy for fUSE5/MCS filamentous phage display vector. The 
fUSE5/MCS vector (8.9 kb) was generated from two other filamentous phage display 
vectors. The fUSE5 phage display vector provided the SfiI restriction enzyme sites in the 
pIII gene for displaying peptides in the pIII coat protein, and the fMCS1 phage display 
vector supplied the MCS for cloning. The MCS from fUSE5/MCS1 was then replaced to 
extend the distance between the BglII and PstI restriction enzyme sites needed for 

























5’ 3’ CMV pA 




incorporation of the targeting peptide ligand on the pIII coat protein (Figure 3). This 
“empty” AAVP vector is easily modifiable for integration of various genes suitable for 
imaging and therapeutic applications into the AvrII and BglII restriction enzyme sites of the 
MCS of the AAV region as well as incorporation of countless targeting peptides into the SfiI 
sites for cloning into the pIII gene for display on the pIII coat protein.  
Construction of the AAVP for targeted delivery of TNF first required integration of 
the TNF gene cassette into the MCS remaining in the AAV segment of the fAAV vector. 
Oligonucleotides were designed for the amplification of the TNF DNA sequence as well as 
addition of restriction enzyme sites specific for XbaI in the sense primer and BamHI in the 
antisense primer (primer set number 2; Table 4). The plasmid containing TNF (pG1SiTNF, 
[1236]) was subjected to PCR amplification using primer set number 2 (Table 4) to amplify 
the TNF sequence. After digestion, the 0.54 kb DNA was subcloned into AvrII and BglII 
Figure 3. Cloning scheme for generation of an AAVP vector (fAAV) for targeted gene 
delivery. The BamHI and SbfI digested fragment (1.8 kb) from pBKS/AAV was 
incorporated into the BglII and PstI restriction enzyme sites of the fUSE5/MCS phage 
display vector to create an “empty” AAVP vector, fAAV (10.7 kb), for targeted gene 
delivery.   	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sites of fAAV. The resulting AAVP vector (fAAV-TNF; 11.2 kb) contained the TNF gene 
cassette under control of the CMV promoter with two SfiI cut sites in the pIII gene of the 
phage display vector for incorporation of the targeting peptide ligand (Figure 4A).  
To generate the octreotide-targeting AAVP for delivery of TNF (Oct-AAVP-TNF), 
an oligonucleotide was designed encoding the octreotide peptide sequence (FCFWKTCT) as 
well as BglI restriction enzyme sites (5′ - GCCNNNNNGGC - 3′) at both terminal regions 
(Table 4). This oligonucleotide was subjected to PCR amplification using primer set number 
3 (Table 4) to generate a double-stranded DNA sequence from the single-stranded 
oligonucleotide. The resulting DNA was digested with BglI and then subcloned into the SfiI 
sites of fAAV-TNF, maintained from fUSE5, to create Oct-AAVP-TNF (11.2 kb; Figure 
4B). The five variable nucleotides in the BglI recognition sequence restrict the ligation into 
the fAAV-TNF in only the appropriate orientation. The inclusion of cysteine residues in the 
pIII gene, when in multiples of two, produces viable viral particles with disulfide bond 
formation between the residues [1237]. The combination of these factors supported the 
correct formation of the octreotide peptide.  
 
 
OCTREOTIDE  DISPLAYED IN A BACTERIOPHAGE  
SYSTEM BINDS SPECIFICALLY TO SSTR2 
 
 Concurrent with the construction of the octreotide-targeted AAVP designed to 
deliver TNF, an octreotide-targeted phage was generated to determine binding affinity for 
SSTR2 and evaluate the feasibility of a phage construct targeted by a biologically active 
peptide, which had not been previously reported. Specific binding with the octreotide-
targeted phage was evaluated in a binding assay against commercially available recombinant 
SSTR proteins immobilized on a microtiter plate. The recombinant proteins were tagged 
with glutathione-S-transferase (GST), so in addition to the experimental BSA control, 
immobilized GST was also used as a negative control. Octreotide-targeted phage bound 
specifically to SSTR2, with no observable binding above background levels evident for 
SSTR1, SSTR3, or SSTR5. Insertless control phage (fd-tet) revealed no binding to any 
SSTR or control proteins (Figure 5A).   
	  	  




































Figure 4. Cloning strategy for construction of octreotide-targeted AAVP delivering 
TNF. (A) The TNF gene cassette was incorporated into the AvrII and BglII sites of the 
fAAV MCS to generate an AAVP vector containing TNF under control of the CMV 
promoter (fAAV-TNF; 11.2 kb). (B) The DNA sequence encoding the octreotide peptide 
sequence and BglI restriction enzyme sites at both terminal regions was subcloned into the 
SfiI sites in the pIII gene for display on the pIII coat protein, generating the targeted AAVP 







































Figure 5. Octreotide-targeted phage binds SSTR2 specifically. (A) Recombinant SSTR 
proteins, GST, or BSA was used to coat duplicate wells of a microtiter plate. Octreotide-
targeted or insertless phage was incubated with the immobilized proteins, and bound phage 
was recovered with bacterial infection and quantified. (B) Octreotide phage binding was 
inhibited with increasing concentrations of synthetic octreotide peptide. Recombinant 
SSTR2 protein was coated on wells of a microtiter plate. Prior to the addition of 
octreotide-targeted or insertless control phage, increasing concentrations of peptide were 
added to duplicate wells for each condition. Bound phage was recovered by bacterial 
infection and quantified. Values indicated are results from a representative example from 
three experiments. Error bars indicate standard deviation of the mean. The symbol *** 
indicates a value of p < 0.001. 	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 To confirm binding specificity, octreotide phage binding to SSTR2 was evaluated 
after administration of increasing concentrations of synthetic octreotide peptide. Binding 
was inhibited in a dose-dependent manner (Figure 5B). Calculations revealed the half 
maximal inhibitory concentration (IC50) to be about 25 nM. These experiments with 
octreotide-targeted phage confirmed recapitulation of the binding activity of the native 
octreotide peptide with specificity for SSTR2 and encouraged continued construction of the 
octreotide-targeted AAVP. 
Upon completion of the octreotide-targeted AAVP-TNF (Oct-AAVP-TNF), binding 
specificity of the AAVP was confirmed in a binding assay identical to the assay previously 
used for the analysis of phage binding. Again, binding was observed for SSTR2 alone, while 
SSTR1, SSTR3, SSTR5 and the control proteins, GST and BSA, showed no binding. 
Insertless control AAVP-TNF revealed no binding to any SSTR or control proteins (Figure 
6). In addition to the sequencing analysis of the targeted AAVP construct, the results of the 


















Figure 6. Octreotide-targeted AAVP-TNF binds SSTR2 specifically. Recombinant 
SSTR proteins tagged with GST, GST alone, or BSA were used to coat duplicate wells of a 
microtiter plate. Octreotide-targeted or insertless control AAVP-TNF was incubated with 
the immobilized proteins, and bound phage was recovered with bacterial infection and 
quantified. Values indicated are results from a representative example of three 
experiments. The Error bars indicate standard deviation of the mean. symbol *** indicates 
a value of p < 0.001. 	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insert into the pIII gene for expression on the viral coat protein encouraging progression to 
evaluation of Oct-AAVP-TNF activity in vitro.  
 
 
 OCT-AAVP-TNF ACTIVITY IN A CELL LINE EXPRESSING SSTR2 
 
 To evaluate Oct-AAVP-TNF activity in vitro, the NCI-H727 NET cell line 
expressing SSTR2 was used [1118, 1238]. SSTR2 expression on the cell surface was 
confirmed in the NCI-H727 cell line using fluorescence-activated cell sorting (FACS) flow 
cytometry analyses with an anti-human SSTR2 antibody. After incubation with the anti-
SSTR2 or isogenic control antibody, FITC-conjugated secondary antibody was added for 
fluorescence sorting with a flow cytometer. Compared to the isogenic control antibody, the 
H727 cells exhibited increased FITC expression corresponding to an increase in anti-SSTR2 
antibody binding (Figure 7). Gating the software parameters for analysis of single, live cells 





Figure 7. NCI-H727 cells express SSTR2. NCI-H727 cells were incubated with an 
antibody specific for human SSTR2 or isotype-matched control (mouse IgG) monoclonal 
antibody followed by a FITC-labeled goat anti-mouse secondary antibody. This histogram 
plot shows the intensity of FITC expression determined by flow cytometry. Cells from 
each experimental group were gated for inclusion of single, live cells from the total cell 
population. The level of FITC expression (x-axis) was compared for the SSTR2 antibody 
experimental group and controls in the same plot. There is a dramatic shift in the anti-
SSTR2 population (red) compared to controls.  
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conditions, and incubating the cell suspension on ice limited receptor internalization and 
allowed evaluation of SSTR2 expression on the cell surface.  
AAVP functionality requires first binding and then internalization into the cells 
expressing the receptor of interest to meditate AAV integration into the cellular genome and 
transgene expression. Both of these cellular activities were evaluated in the NCI-H727 cell 
line expressing SSTR2. Biopanning and rapid analysis of selective interacting ligands 
(BRASIL) cell binding studies allowed evaluation of AAVP binding to receptors displayed 
on the cell surface. Using the NCI-H727 cell line, we evaluated binding of targeted and 
control AAVP-TNF in the presence or absence of synthetic somatostatin peptide. Binding 
with the octreotide-targeted AAVP was significantly increased compared to the insertless 
control AAVP. Incubating the NCI-H727 cells with of synthetic somatostatin peptide prior 
to the addition of AAVP to the cell suspension eliminated Oct-AAVP-TNF binding to NCI-
H727 cells (Figure 8).  
We next evaluated the ability of Oct-AAVP-TNF to internalize into cells using the 
NCI-H727 cell line. Octreotide-targeted, but not insertless control, AAVP-TNF was found 
to internalize into the cells at both two and 24 hours (Figure 9). Analysis of secondary 
antibody alone and an IgG control revealed no fluorescence, indicating no non-specific 
AAVP binding. Lack of immunofluorescence in the non-permeabilized cells confirmed that 
multiple washes with a glycine buffer were sufficient to eliminate bound AAVP from the 
cell surface and indicated the fluorescence in the permeabilized cells was due to internalized 
AAVP alone. Fluorescence was observed in the cytoplasm of the majority of cells after 
administration of Oct-AAVP-TNF, with increasing accumulation observed at the later time 
point. In addition to the clathrin-mediated endocytosis AAVP undergoes upon receptor 
binding [1183, 1186], SSTR internalization also occurs due to exposure to circulating 
ligands, especially at high concentrations [728, 729, 732, 733, 1239, 1240]. The dual modes 
of internalization could be responsible for the large percentage of cells with some evidence 
of fluorescence indicating the presence of the AAVP particles. 
After confirmation of receptor binding and internalization, the NCI-H727 cells were 
evaluated in an experiment to confirm the transduction capabilities of the AAV component 
of the Oct-AAVP-TNF. Because TNF is a secreted protein, incubating the cells with either 
octreotide-targeted or insertless control AAVP allowed for an analysis of TNF expression 
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over time. Cell culture medium collected every two days was analyzed at the conclusion of 
the 10 day experiment to reveal increased TNF expression over time in the octreotide-
targeted, but not insertless control, samples (Figure 10). The level of TNF expression, 
analyzed with an ELISA for anti-human TNF, steadily increased over the 10 days in the 
octreotide wells, while no increase was observed in the wells incubated with insertless 
control AAVP-TNF. This was consistent with transgene expression observed in previous 
studies [1174, 1175, 1183]. No cytotoxic effects were evident in the cells during the study, 
and the cells remained confluent at the end of the ten day study, confirming previous reports 
that indicate a supplemental or synergistic agent must be added to the cells for an observable 
cytotoxic effect [1241-1243]. This is not necessarily the case in vivo where the cytotoxic 
















Figure 8. Oct-AAVP-TNF binds NCI-H727 cells.  Octreotide-targeted, but not insertless 
control, AAVP-TNF was able to bind NCI-H272 cells, and the addition of synthetic 
somatostatin peptide eliminated AAVP binding. After incubation of the cells with the 
AAVP in the presence of absence of synthetic somatostatin peptide, the cells and any 
bound AAVP were separated from unbound AAVP in the aqueous suspension with a 
single differential centrifugation through an organic phase to pellet in the tube. Bacterial 
infection of the cell pellet allowed quantification of bound AAVP in the various 
experimental conditions. Values indicated are results from a representative example of four 
experiments. Error bars indicate standard deviation of the mean. The symbol * indicates a 



































Figure 9. Oct-AAVP-TNF internalizes into NCI-H727 cells.  Octreotide-targeted, but 
not insertless control, AAVP-TNF was found to internalize into NCI-H727 cells after both 
2 and 24 hours incubation. A primary antibody against bacteriophage, capable of 
recognizing the phage-based portion of AAVP, followed by a Cy3-conjugated goat anti-
rabbit secondary antibody, was used to identify AAVP within the cells (red fluorescence). 






OCT-AAVP-TNF ACTIVITY IN THE MEN1 TRANSGENIC MOUSE MODEL 
 
 As described previously, the mouse model of MEN1 syndrome used in this study, 
forms insulin-secreting tumors, or insulinomas, in the islets of the endocrine pancreas. The 
tumor microenvironment of the Men1 transgenic mouse model provides an opportunity to 
Figure 10. TNF expression after transduction with Oct-AAVP-TNF increases over 
time. Octreotide-targeted or control AAVP-TNF was used to transduce NCI-H727 cells. 
Compared to insertless control AAVP, the levels of secreted TNF found in cell culture 
medium 8 and 10 days after transduction in the octreotide group was significantly 
increased. Values indicated are results of a representative example of two experiments. 





















evaluate the activity of the octreotide-targeted AAVP-TNF in a system that mimics the 
vulnerable vasculature found in MEN1 patients. Pancreatic NETs in the Men1 mouse model 
are highly vascularized. In addition to increased density compared to control islets, blood 
vessels in pancreatic NETs of the Men1 mice demonstrate structural abnormalities, 
including dilation and intense tortuosity [54]. Tumors in the Men1 mouse model also 
express SSTR2 for targeting with the octreotide peptide displayed in AAVP [1233]. 
Increased islet vascularity in Men1 transgenic mice correlates with both insulinoma 
development and disease progression [54]. These studies confirmed the suitability of the 
Men1 mouse model for targeted gene delivery using Oct-AAVP-TNF.  
  Insulinomas are functioning tumors with a measureable increase serum insulin 
levels evident in these mice as the tumor progresses [54]. Men1 transgenic mice were 
evaluated prior to the initiation of the study to confirm the presence of an insulin-secreting 
tumor in the animals. Compared to control mice, the Men1 transgenic mice had significantly 
increased serum insulin levels, indicating the presence of functioning NETs (Figure 11). 
With the confirmation of tumor status, AAVP was administered via tail vein injection and 




















Figure 11. Pancreatic NETs of the Men1 transgenic mice are functioning insulinomas. 
Compared to control mice of the same age, 12-month-old Men1 transgenic mice have 
increased levels of circulating insulin, indicating the presence of insulin-secreting tumors 
in the pancreas. Error bars indicate standard deviation of the mean. The symbol *** 
indicates a value of p < 0.001. 
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analyzed for AAVP homing. Octreotide-targeted AAVP-TNF was found to localize 
specifically in the insulinomas of the Men1 mice, but was not found in the islets of control 
mice (Figure 12). Evaluation of normal organs and tissues recovered from the Men1 
transgenic mice revealed the presence of anti-phage fluorescence within the spleen, liver, 
and kidney (Figure 13), consistent with previous studies [30, 1144]. The amount of 
expression appears to be decreased compared to both earlier studies and previous laboratory 
experience, likely as a result of the extended time frame in our study compared to earlier 
reports with localization studies done at time points of 24 hours or less.  
 Transgene expression was also evaluated at both RNA and protein levels to evaluate 
the transduction capabilities of Oct-AAVP-TNF. First, an ELISA assay to evaluate TNF 
protein expression in the pancreas, including the tumors present, and control organs 
identified TNF only in the pancreases of the Men1 transgenic mice but not the pancreases of  
















Figure 12. Oct-AAVP-TNF localizes to insulinomas in the Men1 transgenic mice but 
not islets in the control mice. Using immunofluorescence, evidence of AAVP homing, 
expressed as green fluorescence associated with anti-phage antibody binding, was 
observed in the insulin-secreting tumors of Men1 transgenic mice. Anti-insulin staining, 
indicated in red, indicated the endocrine tissue.  
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experimental group (Figure 14). The lack of TNF expression in the organs of the 
reticuloendothelial system (RES; or mononuclear phagocyte system (MPS)), including the 
spleen, liver, and kidneys was indicative of a lack of cellular transduction in these organs. 
Although the AAVP particles are commonly identified in these organs in phage homing 
studies, and our homing as well (Figure 13), a lack of transgene expression from these 
organs confirms previous reports that this accumulation is a transient artifact of particle 
processing, degradation, and excretion in vivo [30, 1144, 1191, 1245]. Of particular interest 
is the lack of TNF expression in the spleen, since this organ has been shown to be positive 
for SSTR2 expression [1246].  
 Using a quantitative real-time RT-PCR analysis, we were able to measure TNF RNA 
levels and confirm the results of the ELISA analysis, with TNF expression only evident in 
Brain Heart Lung Muscle 
Liver Spleen Kidney 
Figure 13. Oct-AAVP-TNF is found in the organs of the RES, but not the negative 
control tissues of the brain, heart, lung, and muscle. Evaluating the control organs of 
the Men1 transgenic mice revealed evidence of octreotide-targeted AAVP (green 
fluorescence) in the spleen, kidney, and liver, in agreement with previous studies. Non-




appreciable amounts in the pancreas, but not control organs, of the Men1 mice. Laser 
capture microdissection (LCM) enabled evaluation of endocrine tumors and exocrine tissue 
separately to determine the origin of the pancreatic TNF expression. Inclusion of these 
values in the graph revealed the pancreas expression originated solely in the insulin-
secreting tumors of the endocrine pancreas, with no TNF expression found in the exocrine 
tissue (Figure 15). Microdissection of the parathyroid from the thyroid enabled evaluation 
of TNF in an endocrine organ expressing SSTR24 as a control for tumor specificity and not 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4 http://www.proteinatlas.org/ENSG00000180616/normal 
Figure 14. TNF is expressed in the pancreas of Men1 transgenic mice but not 
control mice. TNF expression, measured by ELISA, was significantly higher in the 
pancreases of the Men1 transgenic mice, compared to the control mice. No expression 
was observed in the control organs or blood collected before and after administration of 
the Oct-AAVP-TNF. Values were determined from the analysis of duplicate samples of 
blood or tissue from each of the three animals per group. Error bars indicate standard 




















































































endocrine localization and transduction with the Oct-AAVP-TNF.  
 With this confirmation of Oct-AAVP-TNF localization to insulinomas in the Men1 
transgenic mice and measureable TNF expression in the tumors following our brief study 
period, we concluded that the octreotide-targeted AAVP-TNF is suitable for targeted gene 






















































































Figure 15. TNF in the pancreas of Men1 mice originates solely in the insulinoma. 
Using quantitative real-time RT-PCR, increased TNF expression was found in the 
pancreas compared to control organs. However, measuring the pancreatic tumor and 
exocrine tissue independently, after isolation and extraction by LCM, indicated TNF 
expression is significantly increased in the tumor, with no appreciable TNF expression 
originating the exocrine tissue. Values were determined from the analysis of duplicate 
samples of each tissue from each of the three Men1 transgenic mice. Error bars indicate 






A thorough description of the generation of an AAVP hybrid vector expressing a 
peptide with known biological activity has been provided. This octreotide-targeted AAVP 
was engineered for the delivery of TNF specifically to the NET cells expressing SSTR2. 
Rather than the traditional phage library panning and selection process to identify tumor-
specific ligand/receptor pairs for targeted applications, this project validated a known 
ligand/receptor pair in the phage system as suitable for ligand-directed gene delivery to 
tumor cells specifically. Phage library screenings provide a method to identify receptors 
expressed in the vasculature, typically of a specific tissue or tumor. Further validation to 
confirm receptor identification and expression allows for generation of a targeted imaging or 
therapeutic agent by conjugation of a clinical agent to the identified ligand. However, as our 
study demonstrates, identification and rational selection of a known ligand/receptor pair for 
targeted gene therapy circumvents the use of combinatorial phage libraries for ligand 
discovery and receptor mapping of a specific tumor. After preparation of a phage construct 
targeted by the amino acid sequence of the octreotide peptide, a somatostatin analog used 
clinically for symptomatic relief of hormone hypersecretion and imaging of tumors 
overexpressing SSTR2, we confirmed the selective and specific binding to SSTR2 and then 
generated an AAVP hybrid vector for gene therapy targeted by the octreotide amino acid 
sequence for delivery of TNF. Evaluations in vitro revealed Oct-AAVP-TNF activity in 
NET cells expressing SSTR2. Cell binding, AAVP internalization, and transgene expression 
were described, demonstrating the activity of a phage construct when targeted by a known 
peptide, which had not been previously shown, and encouraging the evaluation of our agent 
in vivo. Confirmation of both ligand-directed homing to pancreatic NETs in the Men1 
transgenic mouse model and TNF expression originating solely from the tumor showed 
activity in a model of human disease.  
Validation of AAVP homing and TNF expression in vitro and in vivo indicated the 
potential clinical utility of our octreotide-targeted AAVP and revealed a new avenue for 
design of gene therapy vectors targeted by known peptide ligands to receptors overexpressed 
in tumors specifically. We were able to demonstrate specific targeting of the tumor, 
	  	  
77	  
significant cellular transduction and gene expression, and no non-specific AAVP binding or 
TNF expression. These results indicate further investigation is warranted using our Oct-
AAVP-TNF in preclinical studies.  The clinical course of this targeted gene therapy could 
feasibly proceed rapidly as a candidate for patients with tumors identified with imaging 
studies utilizing somatostatin receptor scintigraphy. The SRS imaging study could be 
considered an imaging biomarker or a companion diagnostic test for a theranostic approach 
of targeted drug delivery. Clinicians evaluate the applicability of octreotide or other 
somatostatin analogs for treating pancreatic NETs with imaging studies that typically utilize 
radiolabeled octreotide peptide [997]. Therefore, an extension of this reality indicates tumor 
homing and localization of our AAVP targeted with the octreotide amino acid sequence 
should be possible to the same cells and tumor sites revealed in the SRS imaging studies. 
There are, however, caveats in tumor susceptibility regarding SSTR2 expression 
down-regulation in response to octreotide treatment over time [728]. This has been observed 
in the treatment of acromegaly in pituitary tumors where resistance to octreotide is evident 
as a decrease in the effectiveness of octreotide against hormone secretion corresponding to a 
loss of SSTR2 expression in a subset of patients [1247]. This phenomenon is feasibly 
avoidable with the use of somatostatin analogs with a broader receptor binding profile, 
rather than SSTR2 specifically. However, it is possible that the use of octreotide for targeted 
drug delivery, as we propose, rather than long-term symptomatic relief, could diminish this 
resistance, especially with the use of a combinatorial approach including our octreotide-
targeted AAVP. The addition of agents capable of producing a synergistic effect by 
enhancing either AAVP transduction efficiency [1183, 1248] or diminishing the effects of 
inhibitor of apoptosis proteins (IAPs) [1184], could further increase the efficacy of AAVP. 
Furthermore, specific targeting of the tumor cells, as opposed to the tumor vasculature as is 
the case with peptides identified in “mapping” studies done with phage library panning in 
vivo, provides an opportunity for dual or even synergistic combinations of targeted therapy 
agents. Inclusion of an anti-angiogenic agent, possibly an RGD (Arg-Gly-Asp) targeted 
agent known to disrupt the vasculature and provide an anti-tumor response could be one 
combinatorial approach to explore [36, 1144, 1182-1184, 1189, 1191, 1209, 1249]. Islet-
specific vascular zip-codes, previously identified and confirmed for tumor expression in 
NETs of the pancreas in an alternative model of islet tumor formation [298, 1137], could 
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also provide a pancreas-specific anti-vascular therapeutic option capable of supplementing 
tumor cell-specific octreotide activity.  
Initially, however, a long-term therapy study is currently underway to evaluate the 
utility of the octreotide-targeted AAVP-TNF as an anti-tumor agent in the Men1 transgenic 
mouse model. Weekly administration of Oct-AAVP-TNF for four months will provide a 
basis for understanding the efficacy of the targeted therapy in a pre-clinical model 
mimicking human disease. Over the course of the study, serum insulin levels will be 
evaluated routinely in addition to immediately following the first injection. Because the 
Men1 transgenic mice produce functioning insulinomas, analysis of insulin, in addition to 
serial imaging studies, provides an additional measurement for analyzing the tumor response 
to treatment over time. Any biochemical response to the treatment will be supported with an 
analysis of the resected tumors for any decrease in size as well as markers of apoptosis that 
will be evaluated after the four month study. This would provide a new avenue of 
investigation towards the goal of identifying novel agents with activity in pancreatic NETs 
with the aim of not only the promotion of disease stabilization and diminished growth, but 
tumor regression [1250]. Oct-AAVP-TNF could have broader indications than octreotide 
biotherapy in pancreatic NETs as well. While octreotide biotherapy is not indicated 
clinically for the treatment of non-functioning tumors, as these tumors have no secretory-
related syndrome, non-functioning pancreatic NETs do express SSTR2 and can be localized 
by SRS, making them susceptible to ligand-directed gene delivery in our AAVP.  
Additionally, numerous tumors of neuroendocrine origin beyond the pancreas 
express SSTR2, making them possible targets for evaluation with our octreotide-targeted 
AAVP [735, 1251]. These tumors originate in organs of the endocrine system or in tumors 
with a known hormonal component, and the majority of these tumors have been evaluated 
for SSTR2 expression and octreotide avidity using the SRS imaging technique (Table 5).  
Finally, there are multiple known biologically active ligands with their 
corresponding receptors overexpressed in numerous tumor types that are being evaluated 
clinically for their ability to act as clinical agents for targeted drug delivery [1252]. 
Numerous peptide hormones are candidates for display in our AAVP for targeted delivery of 
TNF to tumors and overexpressing the receptors corresponding to the hormone ligands. 
















Pheochromocytoma 60 - 100 40 - 86 [650, 668, 671, 672, 675] Adrenal 
Ganglioneuroma 100  [668] 
Breast Carcinoma 25 - 90 74 - 75 [672, 675, 728, 1253] 
Astrocytoma 82 67 - 100 [672, 675] 




(CNS) Paraganglioma 92 94 - 100 [672, 675, 1256] 
Kidney Renal cell carcinoma 72 100 [1257] 
Lung Small cell lung cancer 50 - 57 63 - 100 










55 - 100 71 - 86 [672, 675, 1247] 
GH-producing 98 70 [672] 
Pituitary 
TSH-producing  100 [672] 
Thyroid Medullary carcinoma 38 - 100 58 - 71 
[668, 672, 675, 
1259] 
Carcinoid 
(bronchial) 68  [649] 
Carcinoid (ileal) 100  [649] 
Carcinoid (ovary) 100  [668] 
Carcinoid (rectum) 91  [668] 
Carcinoid (small 
intestine) 100  [668] 
Carcinoid (testis) 100  [668] 
Carcinoid (thymus) 50  [668] 
Various 
Carcinoid 
(undefined) 80 - 88 77 - 96 
[41, 671, 672, 675, 
880, 1260] 
Table 5. SSTR2 expression and SRS sensitivity in various tumor types  	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(LHRH)) receptor expression in breast and gynecological cancers in women and prostate 
cancer in men [1261] and neurotensin or bombesin receptors found in lung, colon, 
pancreatic, breast, and prostate cancers [1262-1265], are examples. Exploiting these known 
receptors overexpressed in tumors for targeted imaging and therapeutic applications has 
been studied extensively [1266]. However, the utility of a gene therapy approach could 
extend the efficacy of this drug delivery design by easing toxicity concerns and, as is the 
case with octreotide, exploit current clinical imaging standards to identify a patient 
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